Naveed Sattar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3163566/publications.pdf

Version: 2024-02-01

1,197 papers

144,386 citations

160 h-index 336 g-index

1268 all docs

1268 docs citations

1268 times ranked 113823 citing authors

#	Article	IF	CITATIONS
1	Serum antinuclear autoantibodies are associated with measures of oxidative stress and lifestyle factors: analysis of LIPIDOGRAM2015 and LIPIDOGEN2015 studies. Archives of Medical Science, 2023, 19, 1214-1227.	0.9	2
2	Chronic pain and COVID-19 hospitalisation and mortality: a UK Biobank cohort study. Pain, 2023, 164, 84-90.	4.2	5
3	Renin–angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 165-178.	3.0	40
4	Obesity, heart failure, and SGLT2 inhibition: DECLARE-TIMI 58 provides insights. European Heart Journal, 2022, 43, 2968-2970.	2.2	6
5	Association and pathways between shift work and cardiovascular disease: a prospective cohort study of 238 661 participants from UK Biobank. International Journal of Epidemiology, 2022, 51, 579-590.	1.9	12
6	Ramadan fasting: recommendations for patients with cardiovascular disease. Heart, 2022, 108, 258-265.	2.9	23
7	Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease—results of the Immune Metabolic Associations in Psoriatic Arthritis study. Rheumatology, 2022, 61, 1026-1034.	1.9	15
8	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Journal of Preventive Cardiology, 2022, 29, 5-115.	1.8	220
9	Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction, and estimating benefits from novel interventions. European Journal of Preventive Cardiology, 2022, 28, 1991-2000.	1.8	44
10	Sex differences in intraorgan fat levels and hepatic lipid metabolism: implications for cardiovascular health and remission of type 2 diabetes after dietary weight loss. Diabetologia, 2022, 65, 226-233.	6.3	12
11	Flash monitor initiation is associated with improvements in HbA1c levels and DKA rates among people with type 1 diabetes in Scotland: a retrospective nationwide observational study. Diabetologia, 2022, 65, 159-172.	6.3	12
12	Type 2 diabetes risks and determinants in second-generation migrants and mixed ethnicity people of South Asian and African Caribbean descent in the UK. Diabetologia, 2022, 65, 113-127.	6.3	7
13	Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. Circulation, 2022, 145, 158-169.	1.6	18
14	Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional study. Rheumatology International, 2022, 42, 261-271.	3.0	5
15	Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. Circulation, 2022, 145, 565-574.	1.6	59
16	Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. Lancet Diabetes and Endocrinology, the, 2022, 10, 35-45.	11.4	29
17	Comparison of mortality in people with type 1 and type 2 diabetes by age of diagnosis: an incident population-based study in England and Wales. Lancet Diabetes and Endocrinology,the, 2022, 10, 95-97.	11.4	9
18	Foot Ulcer and Risk of Lower Limb Amputation or Death in People With Diabetes: A National Population-Based Retrospective Cohort Study. Diabetes Care, 2022, 45, 83-91.	8.6	36

#	Article	IF	CITATIONS
19	Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A meta-analysis with the FREEDOM cardiovascular outcomes trial. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2022, 16, 102382.	3.6	22
20	Relationship Between Anti-DFS70 Autoantibodies and Oxidative Stress. Biomarker Insights, 2022, 17, 117727192110667.	2.5	1
21	Associations of muscle mass and grip strength with severe NAFLD: A prospective study of 333,295 UK Biobank participants. Journal of Hepatology, 2022, 76, 1021-1029.	3.7	43
22	Osteoporosis and Its Association With Cardiovascular Disease, Respiratory Disease, and Cancer: Findings From the UK Biobank Prospective Cohort Study. Mayo Clinic Proceedings, 2022, 97, 110-121.	3.0	14
23	Disease consequences of higher adiposity uncoupled from its adverse metabolic effects using Mendelian randomisation. ELife, 2022, $11, \dots$	6.0	10
24	Estimating the Effect of Liver and Pancreas Volume and Fat Content on Risk of Diabetes: A Mendelian Randomization Study. Diabetes Care, 2022, 45, 460-468.	8.6	27
25	Type 2 Diabetes Partitioned Polygenic Scores Associate With Disease Outcomes in 454,193 Individuals Across 13 Cohorts. Diabetes Care, 2022, 45, 674-683.	8.6	29
26	Type 2 Diabetes, Glycemic Control, and Their Association With Dementia and Its Major Subtypes: Findings From the Swedish National Diabetes Register. Diabetes Care, 2022, 45, 634-641.	8.6	16
27	Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes. Diabetes Care, 2022, 45, 909-918.	8.6	56
28	Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin. Journal of the American College of Cardiology, 2022, 79, 432-444.	2.8	21
29	Current management and screening of peripheral and coronary artery disease in people with diabetes mellitus in Europe. The PADDIA/CADDIA survey. Diabetes Research and Clinical Practice, 2022, 184, 109214.	2.8	1
30	EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Annals of the Rheumatic Diseases, 2022, 81, 768-779.	0.9	128
31	Glycoprotein Acetyls: A Novel Inflammatory Biomarker of Early Cardiovascular Risk in the Young. Journal of the American Heart Association, 2022, 11, e024380.	3.7	35
32	Muscle protein synthesis and muscle/metabolic responses to resistance exercise training in South Asian and White European men. Scientific Reports, 2022, 12, 2469.	3.3	1
33	Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nature Medicine, 2022, 28, 591-598.	30.7	139
34	No Effect of Levothyroxine on Hemoglobin in Older Adults With Subclinical Hypothyroidism: Pooled Results From 2 Randomized Controlled Trials. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2339-e2347.	3.6	4
35	Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes. Diabetes, Obesity and Metabolism, 2022, 24, 1061-1071.	4.4	15
36	The association between a lifestyle score, socioeconomic status, and COVID-19 outcomes within the UK Biobank cohort. BMC Infectious Diseases, 2022, 22, 273.	2.9	20

#	Article	IF	Citations
37	Young-onset diabetes in Asian Indians is associated with lower measured and genetically determined beta cell function. Diabetologia, 2022, 65, 973-983.	6.3	32
38	Beyond 10-Year Risk: A Cost-Effectiveness Analysis of Statins for the Primary Prevention of Cardiovascular Disease. Circulation, 2022, 145, 1312-1323.	1.6	11
39	Risk scoring in secondary prevention: a basis for informed clinical decisions in the context of ever-expanding treatments. European Heart Journal, 2022, , .	2.2	3
40	Incidence and Characteristics of Remission of Type 2 Diabetes in England: A Cohort Study Using the National Diabetes Audit. Diabetes Care, 2022, 45, 1151-1161.	8.6	21
41	Association of Cardiac Biomarkers With Cardiovascular Outcomes in Patients With Psoriatic Arthritis and Psoriasis: A Longitudinal Cohort Study. Arthritis and Rheumatology, 2022, 74, 1184-1192.	5.6	5
42	Stepâ€byâ€step diagnosis and management of the nocebo/drucebo effect in statinâ€associated muscle symptoms patients: a position paper from <i>the International Lipid Expert Panel</i> (ILEP). Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 1596-1622.	7.3	35
43	Managing weight and glycaemic targets in people with type 2 diabetes—How far have we come?. Endocrinology, Diabetes and Metabolism, 2022, 5, e00330.	2.4	9
44	Estimated Life-Years Gained Free of New or Recurrent Major Cardiovascular Events With the Addition of Semaglutide to Standard of Care in People With Type 2 Diabetes and High Cardiovascular Risk. Diabetes Care, 2022, 45, 1211-1218.	8.6	9
45	Clinical cardiovascular phenotypes and the pattern of future events in patients with type 2 diabetes. Clinical Research in Cardiology, 2022, , 1.	3.3	1
46	Comparing and contrasting risk factors for heart failure in patients with and without history of myocardial infarction: data from <scp>HOMAGE</scp> and the <scp>UK</scp> Biobank. European Journal of Heart Failure, 2022, 24, 976-984.	7.1	5
47	A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk. Science Translational Medicine, 2022, 14, eabj9625.	12.4	31
48	Managing Cardiovascular Risk in Patients with Rheumatic Disease. Rheumatic Disease Clinics of North America, 2022, 48, 429-444.	1.9	4
49	GuÃa ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clÃnica. Revista Espanola De Cardiologia, 2022, 75, 429.e1-429.e104.	1.2	27
50	Handgrip strength and allâ€cause dementia incidence and mortality: findings from the UK Biobank prospective cohort study. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 1514-1525.	7.3	32
51	Genetic analysis of over half a million people characterises C-reactive protein loci. Nature Communications, 2022, 13, 2198.	12.8	48
52	The Association between Serum Lipids and Intraocular Pressure in 2 Large United Kingdom Cohorts. Ophthalmology, 2022, 129, 986-996.	5.2	11
53	Ethnic differences in cardiovascular risk: examining differential exposure and susceptibility to risk factors. BMC Medicine, 2022, 20, 149.	5.5	26
54	Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation. Nature Genetics, 2022, 54, 560-572.	21.4	250

#	Article	IF	CITATIONS
55	The timeâ€varying cardiovascular benefits of glucagonâ€like peptideâ€l receptor agonist therapy in patients with type 2 diabetes mellitus: Evidence from large multinational trials. Diabetes, Obesity and Metabolism, 2022, 24, 1607-1616.	4.4	7
56	Association of gamma-glutamyltransferase levels with total mortality, liver-related and cardiovascular outcomes: A prospective cohort study in the UK Biobank. EClinicalMedicine, 2022, 48, 101435.	7.1	11
57	Associations between reductions in routine care delivery and non-COVID-19-related mortality in people with diabetes in England during the COVID-19 pandemic: a population-based parallel cohort study. Lancet Diabetes and Endocrinology,the, 2022, 10, 561-570.	11.4	32
58	A multisystem, cardio-renal investigation of post-COVID-19 illness. Nature Medicine, 2022, 28, 1303-1313.	30.7	39
59	Severe COVIDâ€19 in people 55 and older during the first year of the pandemic in Sweden. Journal of Internal Medicine, 2022, 292, 641-653.	6.0	7
60	Prognostic Implications of N-Terminal Pro–B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved. JACC: Heart Failure, 2022, 10, 512-524.	4.1	20
61	Left-Sided Degenerative Valvular Heart Disease in Type 1 and Type 2 Diabetes. Circulation, 2022, 146, 398-411.	1.6	10
62	Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). Cardiovascular Diabetology, 2022, 21, .	6.8	3
63	High Circulating Triglycerides Are Most Commonly a Marker of Ectopic Fat Accumulation: Connecting the Clues to Advance Lifestyle Interventions. Circulation, 2022, 146, 77-79.	1.6	5
64	The Common H202D Variant in GDF-15 Does Not Affect Its Bioactivity but Can Significantly Interfere with Measurement of Its Circulating Levels. journal of applied laboratory medicine, The, 2022, 7, 1388-1400.	1.3	8
65	Prevention of CV outcomes in antihyperglycaemic drug-na \tilde{A} -ve patients with type 2 diabetes with, or at elevated risk of, ASCVD: to start or not to start with metformin. European Heart Journal, 2021, 42, 2574-2576.	2.2	11
66	Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF). Circulation, 2021, 143, 516-525.	1.6	237
67	Predictors of type 2 diabetes remission in the Diabetes Remission Clinical Trial (DiRECT). Diabetic Medicine, 2021, 38, e14395.	2.3	53
68	The impact of type of dietary protein, animal versus vegetable, in modifying cardiometabolic risk factors: A position paper from the International Lipid Expert Panel (ILEP). Clinical Nutrition, 2021, 40, 255-276.	5.0	75
69	Psoriatic arthritis is associated with adverse body composition predictive of greater coronary heart disease and type 2 diabetes propensity – a cross-sectional study. Rheumatology, 2021, 60, 1858-1862.	1.9	7
70	Diabetes incidence in a highâ€risk UK population at 7 years: linkage of the Prevention of Diabetes and Obesity in South Asians (PODOSA) trial to the Scottish Diabetes Register. Diabetic Medicine, 2021, 38, e14369.	2.3	2
71	Design and baseline characteristics of the <scp>AMPLITUDEâ€O</scp> cardiovascular outcomes trial of efpeglenatide, a weekly glucagonâ€like peptideâ€l receptor agonist. Diabetes, Obesity and Metabolism, 2021, 23, 318-323.	4.4	12
72	Empagliflozin treatment effects across categories of baseline ⟨scp⟩HbA1c⟨ scp⟩, body weight and blood pressure as an addâ€on to metformin in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2021, 23, 425-433.	4.4	19

#	Article	IF	Citations
73	Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study. Diabetes Care, 2021, 44, 210-216.	8.6	14
74	Association of Circulating Metabolites in Plasma or Serum and Risk of Stroke. Neurology, 2021, 96, .	1.1	24
75	Weight lossâ€induced increase in fasting ghrelin concentration is a predictor of weight regain: Evidence from the Diabetes Remission Clinical Trial (DiRECT). Diabetes, Obesity and Metabolism, 2021, 23, 711-719.	4.4	11
76	Characterization and implications of the initial estimated glomerular filtration rate †dip†upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney International, 2021, 99, 750-762.	5.2	111
77	Reply to: Prognostic implications of vitamin D in patients with COVID-19. European Journal of Nutrition, 2021, 60, 551-551.	3.9	O
78	Skeletal Muscle and Metabolic Health: How Do We Increase Muscle Mass and Function in People with Type 2 Diabetes?. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 309-317.	3.6	11
79	Occupation and risk of severe COVID-19: prospective cohort study of 120 075 UK Biobank participants. Occupational and Environmental Medicine, 2021, 78, 307-314.	2.8	402
80	Testosterone replacement to prevent type 2 diabetes? Not just yet. Lancet Diabetes and Endocrinology, the, 2021, 9, 5-6.	11.4	2
81	Vegetarians, fish, poultry, and meat-eaters: who has higher risk of cardiovascular disease incidence and mortality? A prospective study from UK Biobank. European Heart Journal, 2021, 42, 1136-1143.	2.2	56
82	Adiposity and cardiovascular outcomes in threeâ€yearâ€old children of participants in <scp>UPBEAT</scp> , an <scp>RCT</scp> of a complex intervention in pregnant women with obesity. Pediatric Obesity, 2021, 16, e12725.	2.8	25
83	Vitamin D and COVID-19 infection and mortality in UK Biobank. European Journal of Nutrition, 2021, 60, 545-548.	3.9	93
84	Determinants of Intima-Media ThicknessÂin the Young. JACC: Cardiovascular Imaging, 2021, 14, 468-478.	5.3	43
85	Type-2 diabetes patients at high risk for cardiovascular events: time to challenge the †metformin-always first†m paradigm. European Journal of Preventive Cardiology, 2021, 28, 66-68.	1.8	2
86	Brief formula lowâ€energyâ€diet for relapse management during weight loss maintenance in the Diabetes Remission Clinical Trial (DiRECT). Journal of Human Nutrition and Dietetics, 2021, 34, 472-479.	2.5	10
87	Sex-dimorphic genetic effects and novel loci for fasting glucose and insulin variability. Nature Communications, 2021, 12, 24.	12.8	87
88	Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. European Heart Journal, 2021, 42, 1203-1212.	2.2	114
89	Effect of coronary flow on intracoronary alteplase: a prespecified analysis from a randomised trial. Heart, 2021, 107, 299-312.	2.9	6
90	PCSK9 genetic variants and cognitive abilities: a large-scale Mendelian randomization study. Archives of Medical Science, 2021, 17, 241-244.	0.9	12

#	Article	IF	Citations
91	Genome-wide association study of circulating interleukin 6 levels identifies novel loci. Human Molecular Genetics, 2021, 30, 393-409.	2.9	32
92	Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. Lancet Diabetes and Endocrinology, the, 2021, 9, 82-93.	11.4	251
93	The association of polypharmacy and high-risk drug classes with adverse health outcomes in the Scottish population with type 1 diabetes. Diabetologia, 2021, 64, 1309-1319.	6.3	5
94	Reply to letter of Davie etÂal. regarding the article: "Vitamin D concentrations and COVID-19 infection in UK Biobank―(Hastie etÂal.). Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021, 15, 642.	3.6	0
95	Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. European Heart Journal, 2021, 42, 1742-1756.	2.2	63
96	Marked improvements in glycaemic outcomes following insulin pump therapy initiation in people with type 1 diabetes: a nationwide observational study in Scotland. Diabetologia, 2021, 64, 1320-1331.	6.3	19
97	Managing Cardiovascular Risk in Patients with Rheumatic Disease. Medical Clinics of North America, 2021, 105, 247-262.	2.5	9
98	Potential Effects of Bariatric Surgery on the Incidence of Heart Failure and Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus and Obesity and on Mortality in Patients With Preexisting Heart Failure: A Nationwide, Matched, Observational Cohort Study. Journal of the American Heart Association, 2021, 10, e019323.	3.7	28
99	Predicting major adverse limb events in individuals with type 2 diabetes: Insights from the EXSCEL trial. Diabetic Medicine, 2021, 38, e14552.	2.3	5
100	Meta-analyses of Results From Randomized Outcome Trials Comparing Cardiovascular Effects of SGLT2is and GLP-1RAs in Asian Versus White Patients With and Without Type 2 Diabetes. Diabetes Care, 2021, 44, 1236-1241.	8.6	37
101	A novel approach to increasing community capacity for weight management a volunteer-delivered programme (ActWELL) initiated within breast screening clinics: a randomised controlled trial. International Journal of Behavioral Nutrition and Physical Activity, 2021, 18, 34.	4.6	11
102	Investigating the relationships between unfavourable habitual sleep and metabolomic traits: evidence from multi-cohort multivariable regression and Mendelian randomization analyses. BMC Medicine, 2021, 19, 69.	5.5	14
103	Metformin and carotid intimaâ€media thickness in neverâ€smokers with type <scp>1</scp> diabetes: The <scp>REMOVAL</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 1371-1378.	4.4	11
104	Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study. Cardiovascular Diabetology, 2021, 20, 67.	6.8	27
105	More Evidence for 5-a-Day for Fruit and Vegetables and a Greater Need for Translating Dietary Research Evidence to Practice. Circulation, 2021, 143, 1655-1658.	1.6	5
106	Can biomarkers help find the â€~sweet spot' for treating patients with diabetes?. European Journal of Heart Failure, 2021, 23, 1037-1039.	7.1	0
107	Diverging trends for onset of acute myocardial infarction, heart failure, stroke and mortality in young males: role of changes in obesity and fitness. Journal of Internal Medicine, 2021, 290, 373-385.	6.0	8
108	Multimorbidity and the risk of major adverse kidney events: findings from the UK Biobank cohort. CKJ: Clinical Kidney Journal, 2021, 14, 2409-2419.	2.9	5

#	Article	IF	Citations
109	Empagliflozin facilitates sustained insulin dose reductions in patients with type 2 diabetes and cardiovascular disease: the EMPA-REG OUTCOME trial. Diabetologie Und Stoffwechsel, 2021, 16, .	0.0	0
110	Trajectories in HbA1c and other risk factors among adults with type 1 diabetes by age at onset. BMJ Open Diabetes Research and Care, 2021, 9, e002187.	2.8	13
111	Genome-wide association study of cardiac troponin I in the general population. Human Molecular Genetics, 2021, 30, 2027-2039.	2.9	11
112	Estimating the causal effect of BMI on mortality risk in people with heart disease, diabetes and cancer using Mendelian randomization. International Journal of Cardiology, 2021, 330, 214-220.	1.7	9
113	Levothyroxine Treatment and Cardiovascular Outcomes in Older People With Subclinical Hypothyroidism: Pooled Individual Results of Two Randomised Controlled Trials. Frontiers in Endocrinology, 2021, 12, 674841.	3.5	18
114	Severe COVID-19 in people with type 1 and type 2 diabetes in Sweden: A nationwide retrospective cohort study. Lancet Regional Health - Europe, The, 2021, 4, 100105.	5.6	77
115	Antihypertensive medication needs and blood pressure control with weight loss in the Diabetes Remission Clinical Trial (DiRECT). Diabetologia, 2021, 64, 1927-1938.	6.3	20
116	OP0221â€TARGETED METABOLOMIC PROFILING AND PREDICTION OF CARDIOVASCULAR EVENTS: A PROSPECTIVE STUDY OF PATIENTS WITH PSORIATIC ARTHRITIS AND PSORIASIS. Annals of the Rheumatic Diseases, 2021, 80, 132-133.	0.9	1
117	POS1068â€Cardiac biomarkers are associated with the development of cardiovascular events in patients with psoriatic arthritis and psoriasis. Annals of the Rheumatic Diseases, 2021, 80, 812.2-813.	0.9	0
118	MO481KIDNEY FUNCTION MEASURES AND THE RISK OF CANCER INCIDENCE, CANCER DEATH AND ALL-CAUSE MORTALITY*. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
119	Targeted metabolomic profiling and prediction of cardiovascular events: a prospective study of patients with psoriatic arthritis and psoriasis. Annals of the Rheumatic Diseases, 2021, 80, 1429-1435.	0.9	11
120	Comparison between data-driven clusters and models based on clinical features to predict outcomes in type 2 diabetes: nationwide observational study. Diabetologia, 2021, 64, 1973-1981.	6.3	19
121	Cardiovascular and kidney implications of the initial response in estimated glomerular filtration rate to sodium glucose cotransporter-2 inhibition with empagliflozin: the $\hat{a}\in \hat{c}$ GFR dip $\hat{a}\in \hat{c}$ in EMPA-REG OUTCOME., 2021, 16, .		0
122	The trans-ancestral genomic architecture of glycemic traits. Nature Genetics, 2021, 53, 840-860.	21.4	341
123	Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England. Lancet Diabetes and Endocrinology, the, 2021, 9, 293-303.	11.4	140
124	Meal-induced inflammation: postprandial insights from the Personalised REsponses to Dletary Composition Trial (PREDICT) study in 1000 participants. American Journal of Clinical Nutrition, 2021, 114, 1028-1038.	4.7	43
125	Type 2 Diabetes, Metabolic Traits, and Risk of Heart Failure: A Mendelian Randomization Study. Diabetes Care, 2021, 44, 1699-1705.	8.6	18
126	Ethnic differences in guideline-indicated statin initiation for people with type 2 diabetes in UK primary care, 2006–2019: A cohort study. PLoS Medicine, 2021, 18, e1003672.	8.4	15

#	Article	IF	Citations
127	Cohort profile: National Diabetes Audit for England and Wales. Diabetic Medicine, 2021, 38, e14616.	2.3	21
128	Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. European Heart Journal, 2021, 42, 4442-4451.	2.2	38
129	Are people with metabolically healthy obesity really healthy? A prospective cohort study of 381,363 UK Biobank participants. Diabetologia, 2021, 64, 1963-1972.	6.3	73
130	Development and validation of a cardiovascular risk prediction model in type 1 diabetes. Diabetologia, 2021, 64, 2001-2011.	6.3	22
131	SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. European Heart Journal, 2021, 42, 2439-2454.	2.2	491
132	Association of statin use in older people primary prevention group with risk of cardiovascular events and mortality: a systematic review and meta-analysis of observational studies. BMC Medicine, 2021, 19, 139.	5.5	22
133	Remote history of VTE is associated with severe COVIDâ€19 in middle and older age: UK Biobank cohort study. Journal of Thrombosis and Haemostasis, 2021, 19, 2533-2538.	3.8	5
134	Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases – A position paper from the International Lipid Expert Panel (ILEP). Progress in Cardiovascular Diseases, 2021, 67, 40-52.	3.1	39
135	Family history of diabetes and risk of SARS OVâ€2 in UK Biobank: A prospective cohort study. Endocrinology, Diabetes and Metabolism, 2021, 4, e00283.	2.4	1
136	Association of sarcopenia with incident osteoporosis: a prospective study of 168,682 UK biobank participants. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 1179-1188.	7.3	26
137	Rising Rates and Widening Socioeconomic Disparities in Diabetic Ketoacidosis in Type 1 Diabetes in Scotland: A Nationwide Retrospective Cohort Observational Study. Diabetes Care, 2021, 44, 2010-2017.	8.6	8
138	Risk of mortality among inpatients with COVIDâ€19 and type 2 diabetes: National data from Kuwait. Endocrinology, Diabetes and Metabolism, 2021, 4, e00287.	2.4	7
139	Sex Differences in Cardiac Troponin I and T and the Prediction of Cardiovascular Events in the General Population. Clinical Chemistry, 2021, 67, 1351-1360.	3.2	30
140	Higher thyroid stimulating hormone leads to cardiovascular disease and an unfavorable lipid profile: EVidence from multi-cohort Mendelian randomization and metabolomic profiling. Atherosclerosis, 2021, 331, e40.	0.8	0
141	Obesity as a Risk Factor for Severe COVID-19: Summary of the Best Evidence and Implications for Health Care. Current Obesity Reports, 2021, 10, 282-289.	8.4	41
142	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal, 2021, 42, 3227-3337.	2,2	2,517
143	SurgiCal Obesity Treatment Study (SCOTS): a prospective, observational cohort study on health and socioeconomic burden in treatment-seeking individuals with severe obesity in Scotland, UK. BMJ Open, 2021, 11, e046441.	1.9	2
144	Derivation and Validation of a 10-Year Risk Score for Symptomatic Abdominal Aortic Aneurysm: Cohort Study of Nearly 500 000 Individuals. Circulation, 2021, 144, 604-614.	1.6	9

#	Article	IF	Citations
145	Ethnic differences in prevalence of actionable HbA1c levels in UK Biobank: implications for screening. BMJ Open Diabetes Research and Care, 2021, 9, e002176.	2.8	5
146	Associations between grip strength and incident type 2 diabetes: findings from the UK Biobank prospective cohort study. BMJ Open Diabetes Research and Care, 2021, 9, e001865.	2.8	25
147	Association between sepsis survivorship and long-term cardiovascular outcomes in adults: a systematic review and meta-analysis. Intensive Care Medicine, 2021, 47, 931-942.	8.2	31
148	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine, 2021, 385, 1451-1461.	27.0	2,143
149	Kidney function and cancer risk: An analysis using creatinine and cystatin C in a cohort study. EClinicalMedicine, 2021, 38, 101030.	7.1	24
150	Medical Research Council Hot Topic workshop report: Planning a UK Nutrition and Healthy Life Expectancy Trial. Nutrition Bulletin, 2021, 46, 395-408.	1.8	2
151	Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the ⟨scp⟩EMPAâ€REG OUTCOME⟨/scp⟩ trial. Diabetes, Obesity and Metabolism, 2021, 23, 2775-2784.	4.4	12
152	The genomics of heart failure: design and rationale of the HERMES consortium. ESC Heart Failure, 2021, 8, 5531-5541.	3.1	11
153	Prognostic Importance of NT-proBNP andÂEffect of Empagliflozin in the EMPEROR-Reduced Trial. Journal of the American College of Cardiology, 2021, 78, 1321-1332.	2.8	55
154	Prevention of Diabetes Macrovascular Complications and Heart Failure. Endocrinology and Metabolism Clinics of North America, 2021, 50, 415-430.	3.2	3
155	Secondary Stroke Prevention in Polish Adults: Results from the LIPIDOGRAM2015 Study. Journal of Clinical Medicine, 2021, 10, 4472.	2.4	2
156	Potential contribution of haemoconcentration to changes in lipid variables with empagliflozin in patients with type 2 diabetes: A post hoc analysis of pooled data from four phase 3 randomized clinical trials. Diabetes, Obesity and Metabolism, 2021, 23, 2763-2774.	4.4	4
157	Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. New England Journal of Medicine, 2021, 385, 896-907.	27.0	339
158	Completion of annual diabetes care processes and mortality: A cohort study using the <scp>National Diabetes Audit for England and Wales</scp> . Diabetes, Obesity and Metabolism, 2021, 23, 2728-2740.	4.4	16
159	Thromboembolic Risk in Hospitalized and Nonhospitalized COVID-19 Patients. Mayo Clinic Proceedings, 2021, 96, 2587-2597.	3.0	51
160	Implications of the 2019 American College of Cardiology/American Heart Association Primary Prevention Guidelines and potential value of the coronary artery calcium score among South Asians in the US: The Mediators of Atherosclerosis in South Asians Living in America (MASALA) study. Atherosclerosis, 2021, 334, 48-56.	0.8	7
161	Estimating Cardiovascular Impacts of Drugs for Psoriatic Disease: A Long Way to Go. Journal of Investigative Dermatology, 2021, 141, 2322-2325.	0.7	О
162	Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes and Endocrinology,the, 2021, 9, 653-662.	11.4	437

#	Article	IF	Citations
163	Cardiovascular Outcomes Trials for Weight Loss Interventions: Another Tool for Cardiovascular Prevention?. Circulation, 2021, 144, 1359-1361.	1.6	6
164	3â€Rationale and design of the Medical Research Council Precision medicine with Zibotentan in microvascular angina (PRIZE) trial MRI sub-study., 2021,,.		0
165	Evaluating an Intervention to Increase Cereal Fiber Intake in Children: A Randomized Controlled Feasibility Trial. Journal of Nutrition, 2021, 151, 379-386.	2.9	3
166	Higher thyrotropin leads to unfavorable lipid profile and somewhat higher cardiovascular disease risk: evidence from multi-cohort Mendelian randomization and metabolomic profiling. BMC Medicine, 2021, 19, 266.	5 . 5	11
167	Epidemiology of type 2 diabetes remission in Scotland in 2019: A cross-sectional population-based study. PLoS Medicine, 2021, 18, e1003828.	8.4	14
168	The Differences in the Prevalence of Cardiovascular Disease, Its Risk Factors, and Achievement of Therapeutic Goals among Urban and Rural Primary Care Patients in Poland: Results from the LIPIDOGRAM 2015 Study. Journal of Clinical Medicine, 2021, 10, 5656.	2.4	9
169	Sleep Duration May Not Have Any Effect on The Risk of Stroke: Insights from Mendelian Randomization and Prospective Cohort Studies. Archives of Medical Science, 2021, , .	0.9	0
170	Metabolic Biomarker Discovery for Risk of Peripheral Artery Disease Compared With Coronary Artery Disease: Lipoprotein and Metabolite Profiling of 31 657 Individuals From 5 Prospective Cohorts. Journal of the American Heart Association, 2021, 10, e021995.	3.7	25
171	Dose-response association between device-measured physical activity and incident dementia: a prospective study from UK Biobank. BMC Medicine, 2021, 19, 305.	5.5	14
172	The Association between Coffee and Caffeine Consumption and Renal Function: Insight from Individual-Level Data, Mendelian Randomization, and Meta-Analysis. Archives of Medical Science, 2021, , .	0.9	1
173	The power of genetic diversity in genome-wide association studies of lipids. Nature, 2021, 600, 675-679.	27.8	353
174	Response by Lee et al to Letter Regarding Article, "Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)― Circulation, 2021, 144, e40.	1.6	6
175	Contributions of changes in physical activity, sedentary time, diet and body weight to changes in cardiometabolic risk. International Journal of Behavioral Nutrition and Physical Activity, 2021, 18, 166.	4.6	3
176	Sex differences in the association of risk factors for heart failure incidence and mortality. Heart, 2020, 106, heartjnl-2019-314878.	2.9	18
177	Metabolic Effects of Breaking Prolonged Sitting With Standing or Light Walking in Older South Asians and White Europeans: A Randomized Acute Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 139-146.	3.6	51
178	Meta-analysis of up to 622,409 individuals identifies 40 novel smoking behaviour associated genetic loci. Molecular Psychiatry, 2020, 25, 2392-2409.	7.9	83
179	Association between APOE e4 and white matter hyperintensity volume, but not total brain volume or white matter integrity. Brain Imaging and Behavior, 2020, 14, 1468-1476.	2.1	62
180	Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial. Arthritis and Rheumatology, 2020, 72, 31-40.	5 . 6	136

#	Article	IF	Citations
181	Diabetes drugs and stroke risk: Intensive versus conventional glucoseâ€lowering strategies, and implications of recent cardiovascular outcome trials. Diabetes, Obesity and Metabolism, 2020, 22, 6-15.	4.4	36
182	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2020, 41, 255-323.	2.2	2,811
183	Metabolomics Profile in Depression: A Pooled Analysis of 230 Metabolic Markers in 5283 Cases With Depression and 10,145 Controls. Biological Psychiatry, 2020, 87, 409-418.	1.3	129
184	1-Year Outcomes of Angina Management Guided by Invasive Coronary Function Testing (CorMicA). JACC: Cardiovascular Interventions, 2020, 13, 33-45.	2.9	141
185	Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. Nature Communications, 2020, 11, 163.	12.8	466
186	Comparing the interobserver reproducibility of different regions of interest on multi-parametric renal magnetic resonance imaging in healthy volunteers, patients with heart failure and renal transplant recipients. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2020, 33, 103-112.	2.0	7
187	Predictors of the Acute Postprandial Response to Breaking Up Prolonged Sitting. Medicine and Science in Sports and Exercise, 2020, 52, 1385-1393.	0.4	13
188	Type 2 diabetes-related sex differences in cardiovascular risk: reasons, ramifications, and clinical realities. European Heart Journal, 2020, 41, 1354-1356.	2.2	11
189	Comment on: Lipid screening and statins alongside disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis. Rheumatology, 2020, 59, 453-454.	1.9	2
190	Hepatic Lipoprotein Export and Remission of Human Type 2 Diabetes after Weight Loss. Cell Metabolism, 2020, 31, 233-249.e4.	16.2	102
191	Update on cardiovascular prevention in clinical practice: A position paper of the European Association of Preventive Cardiology of the European Society of Cardiology. European Journal of Preventive Cardiology, 2020, 27, 181-205.	1.8	148
192	Shorter sleep: a new potential target to address cardiovascular and metabolic risk?. Cardiovascular Research, 2020, 116, 1407-1409.	3.8	4
193	Glycated Hemoglobin, Prediabetes, and the Links to Cardiovascular Disease: Data From UK Biobank. Diabetes Care, 2020, 43, 440-445.	8.6	56
194	Potential Benefits and Harms of Gastric Bypass Surgery in Obese Individuals With Type 1 Diabetes: A Nationwide, Matched, Observational Cohort Study. Diabetes Care, 2020, 43, 3079-3085.	8.6	17
195	TCT CONNECT-16 Implications of Impaired Coronary Flow on the Effects of Intracoronary Alteplase During Primary Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2020, 76, B7-B8.	2.8	0
196	Artificial intelligence framework for predictive cardiovascular and stroke risk assessment models: A narrative review of integrated approaches using carotid ultrasound. Computers in Biology and Medicine, 2020, 126, 104043.	7.0	34
197	Role of the Metabolic Profile in Mediating the Relationship Between Body Mass Index and Left Ventricular Mass in Adolescents: Analysis of a Prospective Cohort Study. Journal of the American Heart Association, 2020, 9, e016564.	3.7	5
198	2-year remission of type 2 diabetes and pancreas morphology: a post-hoc analysis of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes and Endocrinology, the, 2020, 8, 939-948.	11.4	74

#	Article	IF	CITATIONS
199	Socioâ€economic status and mortality in people with type 1 diabetes in Scotland 2006–2015: a retrospective cohort study. Diabetic Medicine, 2020, 37, 2081-2088.	2.3	14
200	Association of Factor V Leiden With Subsequent Atherothrombotic Events. Circulation, 2020, 142, 546-555.	1.6	11
201	BMI and future risk for COVID-19 infection and death across sex, age and ethnicity: Preliminary findings from UK biobank. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 1149-1151.	3.6	83
202	Rationale and design of the Medical Research Council's Precision Medicine with Zibotentan in Microvascular Angina (PRIZE) trial. American Heart Journal, 2020, 229, 70-80.	2.7	40
203	Alzheimer's Disease Susceptibility Gene Apolipoprotein E (APOE) and Blood Biomarkers in UK Biobank (N = 395,769). Journal of Alzheimer's Disease, 2020, 76, 1541-1551.	2.6	13
204	Risk Factor Control and Cardiovascular Event Risk in People With Type 2 Diabetes in Primary and Secondary Prevention Settings. Circulation, 2020, 142, 1925-1936.	1.6	54
205	Discovery of rare variants associated with blood pressure regulation through meta-analysis of 1.3 million individuals. Nature Genetics, 2020, 52, 1314-1332.	21.4	91
206	Association of SBP and BMI with cognitive and structural brain phenotypes in UK Biobank. Journal of Hypertension, 2020, 38, 2482-2489.	0.5	20
207	Do nuclear magnetic resonance (NMR)-based metabolomics improve the prediction of pregnancy-related disorders? Findings from a UK birth cohort with independent validation. BMC Medicine, 2020, 18, 366.	5.5	22
208	Comparison of two different frailty measurements and risk of hospitalisation or death from COVID-19: findings from UK Biobank. BMC Medicine, 2020, 18, 355.	5. 5	52
209	The Chief Scientist Office Cardiovascular and Pulmonary Imaging in SARS Coronavirus disease-19 (CISCO-19) study. Cardiovascular Research, 2020, 116, 2185-2196.	3.8	31
210	Does the association between physical capability and mortality differ by deprivation? Findings from the UK Biobank population-based cohort study. Journal of Sports Sciences, 2020, 38, 2732-2739.	2.0	1
211	Understanding How Much TV is Too Much. Mayo Clinic Proceedings, 2020, 95, 2429-2441.	3.0	13
212	Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes and Endocrinology, the, 2020, 8, 823-833.	11.4	677
213	Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes and Endocrinology, the, 2020, 8, 813-822.	11.4	733
214	Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study. Diabetes Care, 2020, 43, 2493-2499.	8.6	29
215	Effects of Canagliflozin on Amino-Terminal Pro–B-Type NatriureticÂPeptide. Journal of the American College of Cardiology, 2020, 76, 2076-2085.	2.8	50
216	A national observation study of cancer incidence and mortality risks in type 2 diabetes compared to the background population over time. Scientific Reports, 2020, 10, 17376.	3.3	37

#	Article	IF	Citations
217	The Upcoming Epidemic of Heart Failure in South Asia. Circulation: Heart Failure, 2020, 13, e007218.	3.9	37
218	Metabolic Age Based on the BBMRI-NL $\langle \sup \rangle 1 \langle \sup \rangle$ H-NMR Metabolomics Repository as Biomarker of Age-related Disease. Circulation Genomic and Precision Medicine, 2020, 13, 541-547.	3.6	50
219	Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine, 2020, 383, 1413-1424.	27.0	2,821
220	Subclinical macro and microvascular disease is differently associated with depressive symptoms in men and women: Findings from the SABRE population-based study. Atherosclerosis, 2020, 312, 35-42.	0.8	0
221	Changes in six domains of cognitive function with reproductive and chronological ageing and sex hormones: a longitudinal study in 2411 UK mid-life women. BMC Women's Health, 2020, 20, 177.	2.0	24
222	Multimorbidity, polypharmacy, and COVID-19 infection within the UK Biobank cohort. PLoS ONE, 2020, 15, e0238091.	2.5	87
223	Effects of Epeleuton, a Novel Synthetic Secondâ€Generation nâ€3 Fatty Acid, on Nonâ€Alcoholic Fatty Liver Disease, Triglycerides, Glycemic Control, and Cardiometabolic and Inflammatory Markers. Journal of the American Heart Association, 2020, 9, e016334.	3.7	17
224	Longitudinal changes in reproductive hormones through the menopause transition in the Avon Longitudinal Study of Parents and Children (ALSPAC). Scientific Reports, 2020, 10, 21258.	3.3	11
225	Response to: "Influence of changes in cholesterol levels and disease activity on the 10-year cardiovascular risk estimated with different algorithms in rheumatoid arthritis patients―by Fornaro et al. Annals of the Rheumatic Diseases, 2020, 79, e105-e105.	0.9	4
226	Plasma fatty acids and the risk of vascular disease and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE study. Diabetologia, 2020, 63, 1637-1647.	6.3	16
227	Physical capability markers used to define sarcopenia and their association with cardiovascular and respiratory outcomes and all-cause mortality: A prospective study from UK Biobank. Maturitas, 2020, 138, 69-75.	2.4	28
228	Vitamin D concentrations and COVID-19 infection in UK Biobank. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 561-565.	3.6	361
229	The obesity paradox in secondary prevention: a weighty intervention or a wait for more evidence?. European Heart Journal, 2020, 41, 2678-2680.	2.2	12
230	Ethnic and socioeconomic differences in SARS-CoV-2 infection: prospective cohort study using UK Biobank. BMC Medicine, 2020, 18, 160.	5.5	307
231	Time trends in deaths before age 50Âyears in people with type 1 diabetes: a nationwide analysis from Scotland 2004–2017. Diabetologia, 2020, 63, 1626-1636.	6.3	6
232	Association of High-Density Lipoprotein Cholesterol With Cognitive Function: Findings From the PROspective Study of Pravastatin in the Elderly at Risk. Journal of Aging and Health, 2020, 32, 1267-1274.	1.7	4
233	Child maltreatment and cardiovascular disease: quantifying mediation pathways using UK Biobank. BMC Medicine, 2020, 18, 143.	5.5	30
234	Mechanisms of Sodium–Glucose Cotransporter 2 Inhibition: Insights From Large-Scale Proteomics. Diabetes Care, 2020, 43, 2183-2189.	8.6	35

#	Article	IF	CITATIONS
235	LB005KIDNEY IMPLICATIONS OF THE INITIAL EGFR RESPONSE TO SGLT2 INHIBITION WITH EMPAGLIFLOZIN: THE â€~EGFR DIP' IN EMPA-REG OUTCOME. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	1
236	Protocol for a randomised controlled trial to investigate the effect of home- and gym-based resistance exercise training on glycaemic control, body composition and muscle strength. Trials, 2020, 21, 557.	1.6	1
237	Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk. Circulation, 2020, 142, 621-642.	1.6	232
238	Optimisation of the ActWELL lifestyle intervention programme for women attending routine NHS breast screening clinics. Trials, 2020, 21, 484.	1.6	5
239	Association of injury related hospital admissions with commuting by bicycle in the UK: prospective population based study. BMJ, The, 2020, 368, m336.	6.0	15
240	Socioâ€economic differences in cardiovascular disease risk factor prevalence in people with type 2 diabetes in Scotland: a crossâ€sectional study. Diabetic Medicine, 2020, 37, 1395-1402.	2.3	4
241	Associations of fat and carbohydrate intake with cardiovascular disease and mortality: prospective cohort study of UK Biobank participants. BMJ, The, 2020, 368, m688.	6.0	81
242	The association of kidney function and cognitive decline in older patients at risk of cardiovascular disease: a longitudinal data analysis. BMC Nephrology, 2020, 21, 81.	1.8	10
243	Renal and Cardiovascular Outcomes After Weight Loss From Gastric Bypass Surgery in Type 2 Diabetes: Cardiorenal Risk Reductions Exceed Atherosclerotic Benefits. Diabetes Care, 2020, 43, 1276-1284.	8.6	43
244	Cardiorenal risk reduction guidance in diabetes: can we reach consensus?. Lancet Diabetes and Endocrinology,the, 2020, 8, 357-360.	11.4	14
245	Improving prevention strategies for cardiometabolic disease. Nature Medicine, 2020, 26, 320-325.	30.7	71
246	Low-Dose Alteplase During Primary Percutaneous Coronary Intervention According to Ischemic Time. Journal of the American College of Cardiology, 2020, 75, 1406-1421.	2.8	16
247	White Blood Cells and Blood Pressure. Circulation, 2020, 141, 1307-1317.	1.6	125
248	The Prospective Studies of Atherosclerosis (Proof-ATHERO) Consortium: Design and Rationale. Gerontology, 2020, 66, 447-459.	2.8	4
249	Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology–Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium–Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or) Tj ETQq1	1 ⁸ 6.78431	4 ¹³ gBT /Ove
250	Body Mass Index in Young Women and Risk of Cardiomyopathy. Circulation, 2020, 141, 520-529.	1.6	31
251	Statin therapy in athletes and patients performing regular intense exercise – Position paper from the International Lipid Expert Panel (ILEP). Pharmacological Research, 2020, 155, 104719.	7.1	17
252	Time Course of Normalization of Functional \hat{l}^2 -Cell Capacity in the Diabetes Remission Clinical Trial After Weight Loss in Type 2 Diabetes. Diabetes Care, 2020, 43, 813-820.	8.6	42

#	Article	IF	CITATIONS
253	Genetic dysregulation of endothelin-1 is implicated in coronary microvascular dysfunction. European Heart Journal, 2020, 41, 3239-3252.	2.2	73
254	GDF15 mediates the effects of metformin on body weight and energy balance. Nature, 2020, 578, 444-448.	27.8	326
255	Effects of Intracoronary Alteplase on Microvascular Function in Acute Myocardial Infarction. Journal of the American Heart Association, 2020, 9, e014066.	3.7	11
256	Metabolic phenotyping by treatment modality in obese women with gestational diabetes suggests diverse pathophysiology: An exploratory study. PLoS ONE, 2020, 15, e0230658.	2.5	9
257	Risk of heart failure in type 2 diabetes complicated by incident ischaemic heart disease and endâ€stage renal disease. European Journal of Heart Failure, 2020, 22, 813-820.	7.1	6
258	Association of types of dietary fats and all-cause and cause-specific mortality: A prospective cohort study and meta-analysis of prospective studies with 1,164,029 participants. Clinical Nutrition, 2020, 39, 3677-3686.	5.0	52
259	Grip Strength and Walking Pace and Cardiovascular Disease Risk Prediction in 406,834 UK Biobank Participants. Mayo Clinic Proceedings, 2020, 95, 879-888.	3.0	41
260	Obesity Is a Risk Factor for Severe COVID-19 Infection. Circulation, 2020, 142, 4-6.	1.6	595
261	Association Between Walking Pace and Stroke Incidence. Stroke, 2020, 51, 1388-1395.	2.0	12
262	Physical activity and lipidomics in a population at high risk of type 2 diabetes mellitus. Journal of Sports Sciences, 2020, 38, 1150-1160.	2.0	7
263	Age-, sex- and ethnicity-related differences in body weight, blood pressure, HbA1c and lipid levels at the diagnosis of type 2 diabetes relative to people without diabetes. Diabetologia, 2020, 63, 1542-1553.	6.3	51
264	The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGRAM2015 study. Atherosclerosis Supplements, 2020, 42, e15-e24.	1.2	18
265	Estimating cardiovascular disease-free life-years with the addition of semaglutide in people with type 2 diabetes using pooled data from SUSTAIN 6 and PIONEER 6. European Heart Journal, 2020, 41, .	2.2	1
266	Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes in chronic kidney disease. Nephrology Dialysis Transplantation, 2020, 35, i43-i47.	0.7	9
267	Modifiable and non-modifiable risk factors for COVID-19, and comparison to risk factors for influenza and pneumonia: results from a UK Biobank prospective cohort study. BMJ Open, 2020, 10, e040402.	1.9	108
268	TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylureaâ€"a MASTERMIND study protocol. BMJ Open, 2020, 10, e042784.	1.9	17
269	How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 506-522.	2.4	39
270	Is older age associated with COVID-19 mortality in the absence of other risk factors? General population cohort study of 470,034 participants. PLoS ONE, 2020, 15, e0241824.	2.5	208

#	Article	IF	Citations
271	Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds/Leeds Teaching Hospitals NHS Trust, LIGHT Laboratories, Clarendon Way. Russian Journal of Cardiology, 2020, 25, 3839.	1.4	10
272	Pharmacological Management of Diabetes for Reducing Glucose Levels and Cardiovascular Disease Risk: What Evidence in South Asians?. Current Diabetes Reviews, 2020, 17, e122820189511.	1.3	3
273	Design and rationale of a nationwide screening analysis from the LIPIDOGRAM2015 and LIPIDOGEN2015 studies. Archives of Medical Science, 2020, 18, 604-616.	0.9	9
274	MON-645 Association of Baseline Cardio-Metabolic Parameters on the Treatment Effects of Empagliflozin When Added to Metformin in Patients with T2D. Journal of the Endocrine Society, 2020, 4, .	0.2	0
275	Low-dose intracoronary alteplase during primary percutaneous coronary intervention in patients with acute myocardial infarction: the T-TIME three-arm RCT. Efficacy and Mechanism Evaluation, 2020, 7, 1-86.	0.7	0
276	Title is missing!. , 2020, 15, e0230658.		0
277	Title is missing!. , 2020, 15, e0230658.		O
278	Title is missing!. , 2020, 15, e0230658.		0
279	Title is missing!. , 2020, 15, e0230658.		O
280	Title is missing!. , 2020, 15, e0230658.		0
281	Title is missing!. , 2020, 15, e0230658.		O
282	Multimorbidity, polypharmacy, and COVID-19 infection within the UK Biobank cohort., 2020, 15, e0238091.		0
283	Multimorbidity, polypharmacy, and COVID-19 infection within the UK Biobank cohort. , 2020, 15, e0238091.		O
284	Multimorbidity, polypharmacy, and COVID-19 infection within the UK Biobank cohort., 2020, 15, e0238091.		0
285	Multimorbidity, polypharmacy, and COVID-19 infection within the UK Biobank cohort., 2020, 15, e0238091.		O
286	What Do Older People Do When Sitting and Why? Implications for Decreasing Sedentary Behavior. Gerontologist, The, 2019, 59, 686-697.	3.9	26
287	Current Smoking and Prognosis AfterÂAcute ST-Segment Elevation MyocardialÂInfarction. JACC: Cardiovascular Imaging, 2019, 12, 993-1003.	5.3	46
288	Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure. Heart, 2019, 105, 307-314.	2.9	28

#	Article	IF	Citations
289	High-Sensitivity Troponin T and Incident Heart Failure in Older Men: British Regional Heart Study. Journal of Cardiac Failure, 2019, 25, 230-237.	1.7	11
290	Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes and Endocrinology,the, 2019, 7, 776-785.	11.4	961
291	A metabolic profile of all-cause mortality risk identified in an observational study of 44,168 individuals. Nature Communications, 2019, 10, 3346.	12.8	188
292	Response by Welsh et al to Letter Regarding Article "Urinary Sodium Excretion, Blood Pressure, and Risk of Future Cardiovascular Disease and Mortality in Subjects Without Prior Cardiovascular Disease― Hypertension, 2019, 74, e27-e28.	2.7	2
293	Da Qing 30 years on: more reasons to extend diabetes prevention. Lancet Diabetes and Endocrinology,the, 2019, 7, 417-419.	11.4	1
294	Evaluation of the effect of sodium–glucose coâ€transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPERORâ€Reduced trial. European Journal of Heart Failure, 2019, 21, 1270-1278.	7.1	155
295	Cardiometabolic comorbidities inÂRAÂand PsA: lessons learned andÂfuture directions. Nature Reviews Rheumatology, 2019, 15, 461-474.	8.0	95
296	Microvascular Disease in Patients With Diabetes With Heart Failure and Reduced Ejection Versus Preserved Ejection Fraction. Diabetes Care, 2019, 42, 1792-1799.	8.6	52
297	Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence. Current Atherosclerosis Reports, 2019, 21, 41.	4.8	53
298	Diabetes management gains: teaching old dogs new tricks. Diabetic Medicine, 2019, 36, 1072-1074.	2.3	1
299	Use of personalised risk-based screening schedules to optimise workload and sojourn time in screening programmes for diabetic retinopathy: A retrospective cohort study. PLoS Medicine, 2019, 16, e1002945.	8.4	12
300	Evaluation of the effects of sodium–glucose coâ€ŧransporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPERORâ€Preserved Trial. European Journal of Heart Failure, 2019, 21, 1279-1287.	7.1	205
301	Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9. BMC Cardiovascular Disorders, 2019, 19, 240.	1.7	22
302	45Association of types of dietary fats and all-cause and cause-specific mortality: a prospective cohort study and meta-analysis of prospective studies with $1,148,117$ participants. European Heart Journal, 2019, 40, .	2.2	1
303	Association of Fitness and Grip Strength With Heart Failure. Mayo Clinic Proceedings, 2019, 94, 2230-2240.	3.0	33
304	Associations of autozygosity with a broad range of human phenotypes. Nature Communications, 2019, 10, 4957.	12.8	84
305	P5313The association between coffee and caffeine consumption and renal function: insight from individual-level data, Mendelian randomization, and meta-analysis. European Heart Journal, 2019, 40, .	2.2	0
306	Impact of Kidney Function on Cardiovascular Risk and Mortality: A Comparison of South Asian and European Cohorts. American Journal of Nephrology, 2019, 50, 425-433.	3.1	14

#	Article	IF	CITATIONS
307	Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease. Nature Medicine, 2019, 25, 1753-1760.	30.7	174
308	Postprandial Vascular Dysfunction Is Associated With Raised Blood Pressure and Adverse Left Ventricular Remodeling in Adolescent Adiposity. Circulation: Cardiovascular Imaging, 2019, 12, e009172.	2.6	4
309	Research digest: new horizons in heart failure therapy. Lancet Diabetes and Endocrinology,the, 2019, 7, 832.	11.4	0
310	Research digest: new insights into established risk pathways. Lancet Diabetes and Endocrinology,the, 2019, 7, 254.	11.4	0
311	Trends in incidence and case fatality of acute myocardial infarction, angina and coronary revascularisation in people with and without type 2 diabetes in Scotland between 2006 and 2015. Diabetologia, 2019, 62, 418-425.	6.3	26
312	Research digest: vitamin D supplementation. Lancet Diabetes and Endocrinology, the, 2019, 7, 91.	11.4	7
313	Exploring the use of adjusted body mass index thresholds based on equivalent insulin resistance for defining overweight and obesity in UK South Asian children. International Journal of Obesity, 2019, 43, 1440-1443.	3.4	1
314	Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet, The, 2019, 393, 407-415.	13.7	512
315	Evidence of a causal relationship between body mass index and psoriasis: A mendelian randomization study. PLoS Medicine, 2019, 16, e1002739.	8.4	144
316	The effect of a lifestyle intervention in obese pregnant women on gestational metabolic profiles: findings from the UK Pregnancies Better Eating and Activity Trial (UPBEAT) randomised controlled trial. BMC Medicine, 2019, 17, 15.	5.5	43
317	Systemic Inflammation and Cardio-Renal Organ Damage Biomarkers in Middle Age Are Associated With Physical Capability Up to 9 Years Later. Circulation, 2019, 139, 1988-1999.	1.6	23
318	Excess Cardiovascular Risk in Type 1 Diabetes Mellitus. Circulation, 2019, 139, 744-747.	1.6	30
319	Epidemiology, risk factors, and opportunities for prevention of cardiovascular disease in individuals of South Asian ethnicity living in Europe. Atherosclerosis, 2019, 286, 105-113.	0.8	40
320	Association of central adiposity with psoriasis, psoriatic arthritis and rheumatoid arthritis: a cross-sectional study of the UK Biobank. Rheumatology, 2019, 58, 2137-2142.	1.9	16
321	Effects of dietary and physical activity interventions on the risk of type 2 diabetes in South Asians: meta-analysis of individual participant data from randomised controlled trials. Diabetologia, 2019, 62, 1337-1348.	6.3	40
322	The association of grip strength with health outcomes does not differ if grip strength is used in absolute or relative terms: a prospective cohort study. Age and Ageing, 2019, 48, 684-691.	1.6	49
323	Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease. Circulation, 2019, 140, 542-552.	1.6	118
324	Sex-based associations with microvascular injury and outcomes after ST-segment elevation myocardial infarction. Open Heart, 2019, 6, e000979.	2.3	7

#	Article	IF	CITATIONS
325	Understanding the mechanisms of reversal of type 2 diabetes. Lancet Diabetes and Endocrinology, the, 2019, 7, 726-736.	11.4	163
326	Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure. Circulation: Heart Failure, 2019, 12, e005897.	3.9	63
327	Research digest: SGLT2 inhibition in kidney and liver disease. Lancet Diabetes and Endocrinology,the, 2019, 7, 427.	11.4	6
328	Do physical activity, commuting mode, cardiorespiratory fitness and sedentary behaviours modify the genetic predisposition to higher BMI? Findings from a UK Biobank study. International Journal of Obesity, 2019, 43, 1526-1538.	3.4	13
329	Higher Body Mass Index in Adolescence Predicts Cardiomyopathy Risk in Midlife. Circulation, 2019, 140, 117-125.	1.6	52
330	Association between fat mass through adolescence and arterial stiffness: a population-based study from The Avon Longitudinal Study of Parents and Children. The Lancet Child and Adolescent Health, 2019, 3, 474-481.	5.6	45
331	Sugar-sweetened beverages intake associates with all-cause mortality independently of other dietary and lifestyle factors and obesity. Proceedings of the Nutrition Society, 2019, 78, .	1.0	1
332	Glycaemic control trends in people with type 1 diabetes in Scotland 2004–2016. Diabetologia, 2019, 62, 1375-1384.	6.3	45
333	Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts. BMC Medicine, 2019, 17, 95.	5.5	192
334	Mendelian randomization evaluation of causal effects of fibrinogen on incident coronary heart disease. PLoS ONE, 2019, 14, e0216222.	2.5	17
335	Cardiac Troponin T and Troponin I in the General Population. Circulation, 2019, 139, 2754-2764.	1.6	200
336	PATIENTS WITH DIABETES AND PERIPHERAL ARTERIAL DISEASE: RESULTS FROM THE EXSCEL TRIAL. Journal of the American College of Cardiology, 2019, 73, 2040.	2.8	1
337	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. Circulation Genomic and Precision Medicine, 2019, 12, e002470.	3.6	17
338	Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. Circulation Genomic and Precision Medicine, 2019, 12, e002471.	3.6	22
339	Lower carbohydrate diets and all-cause and cause-specific mortality: a population-based cohort study and pooling of prospective studies. European Heart Journal, 2019, 40, 2870-2879.	2.2	103
340	Cardiovascular Risk and Risk Factor Management in Type 2 Diabetes Mellitus. Circulation, 2019, 139, 2742-2753.	1.6	81
341	Assessing for interaction between <i>APOE</i> $\hat{l}\mu 4$, sex, and lifestyle on cognitive abilities. Neurology, 2019, 92, e2691-e2698.	1.1	28
342	BMI, Mortality, and Cardiovascular Outcomes in Type 1 Diabetes: Findings Against an Obesity Paradox. Diabetes Care, 2019, 42, 1297-1304.	8.6	47

#	Article	IF	Citations
343	A Multicenter, Randomized, Placeboâ€Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis. Arthritis and Rheumatology, 2019, 71, 1437-1449.	5.6	77
344	The Combination of Physical Activity and Sedentary Behaviors Modifies the Genetic Predisposition to Obesity. Obesity, 2019, 27, 653-661.	3.0	5
345	Excess mortality and cardiovascular disease risk in type 1 diabetes – Authors' reply. Lancet, The, 2019, 393, 985-986.	13.7	2
346	Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010–2017. Diabetes, Obesity and Metabolism, 2019, 21, 1576-1584.	4.4	64
347	Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality. Circulation, 2019, 139, 1458-1460.	1.6	49
348	High-throughput quantification of carboxymethyl lysine in serum and plasma using high-resolution accurate mass Orbitrap mass spectrometry. Annals of Clinical Biochemistry, 2019, 56, 397-407.	1.6	4
349	Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 344-355.	11.4	569
350	Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks. Circulation, 2019, 139, 2228-2237.	1.6	305
351	Urinary Sodium Excretion, Blood Pressure, and Risk of Future Cardiovascular Disease and Mortality in Subjects Without Prior Cardiovascular Disease. Hypertension, 2019, 73, 1202-1209.	2.7	54
352	Dose-response associations of cardiorespiratory fitness with all-cause mortality and incidence and mortality of cancer and cardiovascular and respiratory diseases: the UK Biobank cohort study. British Journal of Sports Medicine, 2019, 53, 1371-1378.	6.7	70
353	The effect of a programme to improve men's sedentary time and physical activity: The European Fans in Training (EuroFIT) randomised controlled trial. PLoS Medicine, 2019, 16, e1002736.	8.4	61
354	Walking Pace Is Associated with Lower Risk of All-Cause and Cause-Specific Mortality. Medicine and Science in Sports and Exercise, 2019, 51, 472-480.	0.4	44
355	Relative Prognostic Importance and Optimal Levels of Risk Factors for Mortality and Cardiovascular Outcomes in Type 1 Diabetes Mellitus. Circulation, 2019, 139, 1900-1912.	1.6	108
356	Advances in the clinical management of type 2 diabetes: a brief history of the past 15 years and challenges for the future. BMC Medicine, 2019, 17, 46.	5.5	18
357	FRIO431â€EFFECT OF PHOSPHODIESTERASE 4 INHIBITION WITH APREMILAST ON BODY WEIGHT AND VASCUL FUNCTION IN PSORIATIC ARTHRITIS â€" INITIAL RESULTS FROM THE IMMUNE METABOLIC ASSOCIATIONS IN PSORIATIC ARTHRITIS (IMAPA) STUDY., 2019,,.	.AR	1
358	P27â€Changes in cognitive function with the menopausal transition: a longitudinal study in ALSPAC women. , 2019, , .		0
359	P6517Three-year clinical outcome of patients with abnormal glucose metabolism treated with contemporary drug-eluting stents. European Heart Journal, 2019, 40, .	2.2	0
360	Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults. BMJ: British Medical Journal, 2019, 367, 15367.	2.3	175

#	Article	IF	CITATIONS
361	Contribution of type 2 diabetes to all-cause mortality, cardiovascular disease incidence and cancer incidence in white Europeans and South Asians: findings from the UK Biobank population-based cohort study. BMJ Open Diabetes Research and Care, 2019, 7, e000765.	2.8	15
362	Yoga and Cardiovascular Health Trial (YACHT): a UK-based randomised mechanistic study of a yoga intervention plus usual care versus usual care alone following an acute coronary event. BMJ Open, 2019, 9, e030119.	1.9	17
363	Population-based secular trends in lower-extremity amputation for diabetes and peripheral artery disease. Cmaj, 2019, 191, E955-E961.	2.0	47
364	Management of Lipid Abnormalities in Patients with Diabetes. Current Cardiology Reports, 2019, 21, 147.	2.9	15
365	Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease. Circulation: Cardiovascular Interventions, 2019, 12, e008018.	3.9	25
366	Menopausal hot flashing and endothelial function in two vascular beds. Menopause, 2019, 26, 1002-1009.	2.0	0
367	Authors' reply to McKenna-Barry and Ryan. BMJ, The, 2019, 367, l6549.	6.0	0
368	Response by Sattar et al to Letters Regarding Article, "Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks― Circulation, 2019, 140, e724-e725.	1.6	2
369	Ischemia and No Obstructive Coronary Artery Disease. Circulation: Cardiovascular Interventions, 2019, 12, e008126.	3.9	107
370	Contrasting Associations of Body Mass Index and Hemoglobin A1c on the Excess Risk of Acute Myocardial Infarction and Heart Failure in Type 2 Diabetes Mellitus. Journal of the American Heart Association, 2019, 8, e013871.	3.7	12
371	Response by Welsh et al to Letter Regarding Article, "Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Diseaseâ€, Circulation, 2019, 140, e824-e825.	1.6	1
372	Consumption of dairy product and its association with total and causeÂspecific mortality – A population-based cohort study and meta-analysis. Clinical Nutrition, 2019, 38, 2833-2845.	5.0	50
373	Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies. European Heart Journal, 2019, 40, 621-631.	2.2	97
374	Heart Failure Epidemiology in Patients With Diabetes Mellitus Without Coronary Heart Disease. Journal of Cardiac Failure, 2019, 25, 78-86.	1.7	22
375	Effect of Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention on Microvascular Obstruction in Patients With Acute Myocardial Infarction. JAMA - Journal of the American Medical Association, 2019, 321, 56.	7.4	88
376	Impact of Obesity on Cardiovascular Disease. Endocrinology, 2019, , 273-293.	0.1	1
377	The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study. Diabetologia, 2019, 62, 621-632.	6.3	33
378	Diabetic cardiomyopathy. Heart, 2019, 105, 337-345.	2.9	60

#	Article	IF	CITATIONS
379	Exome Chip Meta-analysis Fine Maps Causal Variants and Elucidates the Genetic Architecture of Rare Coding Variants in Smoking and AlcoholÂUse. Biological Psychiatry, 2019, 85, 946-955.	1.3	69
380	Associations of dietary protein intake with bone mineral density: An observational study in 70,215 UK Biobank participants. Bone, 2019, 120, 38-43.	2.9	10
381	The association between driving time and unhealthy lifestyles: a cross-sectional, general population study of 386 493 UK Biobank participants. Journal of Public Health, 2019, 41, 527-534.	1.8	2
382	Cardiovascular disease prevalence and risk factor prevalence in Type 2 diabetes: a contemporary analysis. Diabetic Medicine, 2019, 36, 718-725.	2.3	46
383	Morning plasma cortisol as a cardiovascular risk factor: findings from prospective cohort and Mendelian randomization studies. European Journal of Endocrinology, 2019, 181, 429-438.	3.7	55
384	Reply to the letter to the editor regarding the article "Prediabetes and its impact on clinical outcome after coronary intervention in a broad patient population― EuroIntervention, 2019, 14, e1621-e1622.	3.2	0
385	Associations of cord leptin and cord insulin with adiposity and blood pressure in White British and Pakistani children aged 4/5 years. Wellcome Open Research, 2019, 4, 157.	1.8	5
386	Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Angina (CorMicA) stratified medicine clinical trial. American Heart Journal, 2018, 201, 86-94.	2.7	22
387	A Rapid (Differential) Effect of Rosuvastatin and Atorvastatin on Highâ€Sensitivity Cardiac Troponinâ€I in Subjects With Stable Cardiovascular Disease. Clinical Pharmacology and Therapeutics, 2018, 104, 311-316.	4.7	6
388	1.4-O8Progression to diabetes in Indian and Pakistani adults with impaired glycaemia in central Scotland: follow-up by record linkage in the PODOSA trial (Prevention of Diabetes & Obesity in South) Tj ETQq0	O OorgBT /	Ov e rlock 10 T
389	Association of Total and Differential Leukocyte Counts With Cardiovascular Disease and Mortality in the UK Biobank. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 1415-1423.	2.4	69
390	Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes. Nature Genetics, 2018, 50, 559-571.	21.4	356
391	Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599â€^912 current drinkers in 83 prospective studies. Lancet, The, 2018, 391, 1513-1523.	13.7	858
392	Pre-conception maternal erythrocyte saturated to unsaturated fatty acid ratio predicts pregnancy after natural cycle frozen embryo transfer. Scientific Reports, 2018, 8, 1216.	3.3	5
393	Personalised blood pressure ranges in type 2 diabetes?. Lancet Diabetes and Endocrinology,the, 2018, 6, 761-763.	11.4	1
394	Research digest: progress in microvascular complications. Lancet Diabetes and Endocrinology,the, 2018, 6, 93.	11.4	4
395	Objectively measured physical activity and cardiac biomarkers: A cross sectional population based study in older men. International Journal of Cardiology, 2018, 254, 322-327.	1.7	9
396	"Silent―Diabetes and Clinical Outcome After Treatment With Contemporary Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2018, 11, 448-459.	2.9	22

#	Article	IF	Citations
397	Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy. Diabetes Care, 2018, 41, 705-712.	8.6	67
398	Genome-wide association study in 79,366 European-ancestry individuals informs the genetic architecture of 25-hydroxyvitamin D levels. Nature Communications, 2018, 9, 260.	12.8	295
399	Red and processed meat consumption and breast cancer: UK Biobank cohort study and meta-analysis. European Journal of Cancer, 2018, 90, 73-82.	2.8	68
400	The effects of remote ischaemic preconditioning on coronary artery function in patients with stable coronary artery disease. International Journal of Cardiology, 2018, 252, 24-30.	1.7	15
401	Short-term progression of cardiometabolic risk factors in relation to age at type 2 diabetes diagnosis: a longitudinal observational study of 100,606 individuals from the Swedish National Diabetes Register. Diabetologia, 2018, 61, 599-606.	6.3	57
402	BMI and Mortality in Patients With New-Onset Type 2 Diabetes: A Comparison With Age- and Sex-Matched Control Subjects From the General Population. Diabetes Care, 2018, 41, 485-493.	8.6	29
403	Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial. Diabetologia, 2018, 61, 1581-1591.	6.3	76
404	Maternal thyroid function and child educational attainment: prospective cohort study. BMJ: British Medical Journal, 2018, 360, k452.	2.3	34
405	Research digest: updates on diabetes in pregnancy. Lancet Diabetes and Endocrinology,the, 2018, 6, 272.	11.4	0
406	The impact of confounding on the associations of different adiposity measures with the incidence of cardiovascular disease: a cohort study of 296 535 adults of white European descent. European Heart Journal, 2018, 39, 1514-1520.	2.2	143
407	Prevalent and Incident Heart Failure inÂCardiovascular Outcome Trials of Patients With Type 2 Diabetes. Journal of the American College of Cardiology, 2018, 71, 1379-1390.	2.8	50
408	Large-scale pharmacogenomic study of sulfonylureas and the QT, JT and QRS intervals: CHARGE Pharmacogenomics Working Group. Pharmacogenomics Journal, 2018, 18, 127-135.	2.0	12
409	Cannabis use and risk of schizophrenia: a Mendelian randomization study. Molecular Psychiatry, 2018, 23, 1287-1292.	7.9	167
410	Incident ischaemic stroke and Type 2 diabetes: trends in incidence and case fatality in Scotland 2004–2013. Diabetic Medicine, 2018, 35, 99-106.	2.3	19
411	Type 2 diabetes, socioeconomic status and life expectancy in Scotland (2012–2014): a population-based observational study. Diabetologia, 2018, 61, 108-116.	6.3	42
412	Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: REDâ€HF study. European Journal of Heart Failure, 2018, 20, 268-277.	7.1	42
413	Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission. Diabetes Care, 2018, 41, 341-347.	8.6	92
414	Men across a range of ethnicities have a higher prevalence of diabetes: findings from a crossâ€sectional study of 500 000 <scp>UK</scp> Biobank participants. Diabetic Medicine, 2018, 35, 270-276.	2.3	16

#	Article	IF	CITATIONS
415	Effect of nonâ€surgical weight management on weight and glycaemic control in people with type 2 diabetes: A comparison of interventional and nonâ€interventional outcomes at 3 years. Diabetes, Obesity and Metabolism, 2018, 20, 879-888.	4.4	6
416	Nuclear magnetic resonanceâ€based metabolomics identifies phenylalanine as a novel predictor of incident heart failure hospitalisation: results from PROSPER and FINRISK 1997. European Journal of Heart Failure, 2018, 20, 663-673.	7.1	47
417	Clinical and metabolic features of the randomised controlled Diabetes Remission Clinical Trial (DiRECT) cohort. Diabetologia, 2018, 61, 589-598.	6.3	46
418	Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet, The, 2018, 391, 541-551.	13.7	1,282
419	Persistent Iron Within the Infarct CoreÂAfter ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Imaging, 2018, 11, 1248-1256.	5.3	43
420	Effect of Evolocumab on Lipoprotein Particles. American Journal of Cardiology, 2018, 121, 308-314.	1.6	29
421	Diabetes, driving and fasting during Ramadan: the interplay between secular and religious law. BMJ Open Diabetes Research and Care, 2018, 6, e000520.	2.8	18
422	Rationale and design of the Coronary Microvascular Angina Cardiac Magnetic Resonance Imaging (CorCMR) diagnostic study: the CorMicA CMR sub-study. Open Heart, 2018, 5, e000924.	2.3	12
423	<i>In vivo</i> multiplex molecular imaging of vascular inflammation using surface-enhanced Raman spectroscopy. Theranostics, 2018, 8, 6195-6209.	10.0	56
424	Randomised controlled trial to assess the impact of a lifestyle intervention (ActWELL) in women invited to NHS breast screening. BMJ Open, 2018, 8, e024136.	1.9	17
425	P2.17-22 Cardiac Biomarkers in CART Study (CARdiac Toxicity in Lung Cancer Patients After) Tj ETQq1 1 0.78431	.4 _{[g} BT /O	verlock 10 Ti
426	Research digest: genetics in cardiometabolic disease. Lancet Diabetes and Endocrinology,the, 2018, 6, 922.	11.4	0
427	Scientific Business Abstracts of the 112th Annual Meeting of the Association of Physicians of Great Britain and Ireland. QJM - Monthly Journal of the Association of Physicians, 2018, 111, 920-924.	0.5	0
428	Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients With Preexisting Cardiovascular Disease. Circulation, 2018, 138, 2576-2578.	1.6	13
429	Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment. Circulation, 2018, 138, 2499-2512.	1.6	69
430	Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. Nature Genetics, 2018, 50, 1505-1513.	21.4	1,331
431	Clinical management of type 2 diabetes in south Asia. Lancet Diabetes and Endocrinology,the, 2018, 6, 979-991.	11.4	49
432	Research digest: CV trials in diabetes—looking ahead. Lancet Diabetes and Endocrinology,the, 2018, 6, 769.	11.4	0

#	Article	IF	Citations
433	BMI and Mortality in UK Biobank: Revised Estimates Using Mendelian Randomization. Obesity, 2018, 26, 1796-1806.	3.0	65
434	VLCD for weight loss and remission of type 2 diabetes? – Authors' reply. Lancet, The, 2018, 392, 1307.	13.7	5
435	Lipoprotein(a) testing experience in a specialist lipid clinic in scotland suggests a need to more commonly measure. Atherosclerosis, 2018, 275, e159-e160.	0.8	0
436	Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight Pathways that Link Inflammation and Complex Disorders. American Journal of Human Genetics, 2018, 103, 691-706.	6.2	326
437	Understanding what we mean by the obesity paradox. European Heart Journal, 2018, 39, 3673-3673.	2.2	3
438	Research digest: assessment and risks of obesity. Lancet Diabetes and Endocrinology, the, 2018, 6, 442.	11.4	2
439	Apolipoprotein CIII and N-terminal prohormone b-type natriuretic peptide as independent predictors for cardiovascular disease in type 2 diabetes. Atherosclerosis, 2018, 274, 182-190.	0.8	12
440	Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies. Diabetes Therapy, 2018, 9, 1317-1334.	2.5	21
441	Response to: â€ [*] On the approach for determining association between changes in marital quality and cardiovascular disease risk factors' by MM Pike. Journal of Epidemiology and Community Health, 2018, 72, 759.2-760.	3.7	0
442	Non-alcoholic fatty liver disease and relative risk of incident steatohepatitis, cirrhosis and hepatocellular carcinoma events in four European primary care databases. Journal of Hepatology, 2018, 68, S57-S58.	3.7	1
443	Non-invasive liver tests in electronic health records of patients with non-alcoholic fatty liver disease: combined analysis from four European countries. Journal of Hepatology, 2018, 68, S551-S552.	3.7	0
444	Associations of Dietary Protein Intake With Fat-Free Mass and Grip Strength: A Cross-Sectional Study in 146,816 UK Biobank Participants. American Journal of Epidemiology, 2018, 187, 2405-2414.	3.4	23
445	Pathways to Cardiorenal Complications in Type 2 Diabetes Mellitus. Circulation, 2018, 138, 7-9.	1.6	35
446	O10â€fThe association of high sensitivity troponin levels with subsequent cardiovascular mortality in an inflammatory arthritis cohort: results from the Norfolk arthritis register. Rheumatology, 2018, 57, .	1.9	0
447	Adiposity-Mortality Relationships in Type 2 Diabetes, Coronary Heart Disease, and Cancer Subgroups in the UK Biobank, and Their Modification by Smoking. Diabetes Care, 2018, 41, 1878-1886.	8.6	30
448	Incidence of Hospitalization for Heart Failure and Case-Fatality Among 3.25 Million People With and Without Diabetes Mellitus. Circulation, 2018, 138, 2774-2786.	1.6	139
449	Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial. Diabetologia, 2018, 61, 2155-2163.	6.3	133
450	Remission of Human Type 2 Diabetes Requires Decrease in Liver and Pancreas Fat Content but Is Dependent upon Capacity for \hat{I}^2 Cell Recovery. Cell Metabolism, 2018, 28, 547-556.e3.	16.2	257

#	Article	IF	Citations
451	Assessing the Causal Role of Body Mass Index on Cardiovascular Health in Young Adults. Circulation, 2018, 138, 2187-2201.	1.6	55
452	Research digest: heart failure in diabetes comes into focus. Lancet Diabetes and Endocrinology,the, 2018, 6, 603.	11.4	3
453	Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data. Diabetes Care, 2018, 41, 1844-1853.	8.6	91
454	432 Investigating a causal relationship between body mass index and inflammatory skin disease using mendelian randomisation. Journal of Investigative Dermatology, 2018, 138, S73.	0.7	0
455	Associations of discretionary screen time with mortality, cardiovascular disease and cancer are attenuated by strength, fitness and physical activity: findings from the UK Biobank study. BMC Medicine, 2018, 16, 77.	5.5	65
456	Dietary and physical activity recommendations to prevent type 2 diabetes in South Asian adults: A systematic review. PLoS ONE, 2018, 13, e0200681.	2.5	17
457	Hypertension, Microvascular Pathology, and Prognosis After an Acute Myocardial Infarction. Hypertension, 2018, 72, 720-730.	2.7	33
458	Gestational diabetes modifies the association between PIGF in early pregnancy and preeclampsia in women with obesity. Pregnancy Hypertension, 2018, 13, 267-272.	1.4	16
459	Performance of Cardiovascular Disease Risk Scores in People Diagnosed With Type 2 Diabetes: External Validation Using Data From the National Scottish Diabetes Register. Diabetes Care, 2018, 41, 2010-2018.	8.6	47
460	Metabolic characterization of menopause: cross-sectional and longitudinal evidence. BMC Medicine, 2018, 16, 17.	5.5	91
461	Excess risk of hospitalisation for heart failure among people with type 2 diabetes. Diabetologia, 2018, 61, 2300-2309.	6.3	31
462	Comparison between High-Sensitivity Cardiac Troponin T and Cardiac Troponin I in a Large General Population Cohort. Clinical Chemistry, 2018, 64, 1607-1616.	3.2	101
463	2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 2018, 39, 3021-3104.	2.2	6,826
464	Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease. BMC Medicine, 2018, 16, 130.	5.5	177
465	Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 2018, 379, 633-644.	27.0	888
466	Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Lancet, The, 2018, 392, 477-486.	13.7	492
467	Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a <i>post hoc</i> analysis of the <scp>AWARD</scp> programme. Diabetic Medicine, 2018, 35, 1434-1439.	2.3	59
468	Association of <i>LPA </i> Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies. JAMA Cardiology, 2018, 3, 619.	6.1	428

#	Article	IF	Citations
469	Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. Nature Genetics, 2018, 50, 26-41.	21.4	286
470	Associations of grip strength with cardiovascular, respiratory, and cancer outcomes and all cause mortality: prospective cohort study of half a million UK Biobank participants. BMJ: British Medical Journal, 2018, 361, k1651.	2.3	412
471	Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT. Health Technology Assessment, 2018, 22, 1-64.	2.8	28
472	Prediabetes and its impact on clinical outcome after coronary intervention in a broad patient population. EuroIntervention, 2018, 14, e1049-e1056.	3.2	34
473	The association between physical activity and risk of mortality is modulated by grip strength and cardiorespiratory fitness: evidence from 498 135 UK-Biobank participants. European Heart Journal, 2017, 38, ehw249.	2.2	107
474	Associations between single and multiple cardiometabolic diseases and cognitive abilities in 474 129 UK Biobank participants. European Heart Journal, 2017, 38, ehw528.	2.2	47
475	Programming of adiposity in childhood and adolescence: associations with birth weight and cord blood adipokines. Journal of Clinical Endocrinology and Metabolism, 2017, 102, jc.2016-2342.	3.6	38
476	Time spent in sedentary posture is associated with waist circumference and cardiovascular risk. International Journal of Obesity, 2017, 41, 689-696.	3.4	37
477	Rare and low-frequency coding variants alter human adult height. Nature, 2017, 542, 186-190.	27.8	544
478	Association between grip strength and diabetes prevalence in black, Southâ€Asian, and white European ethnic groups: a crossâ€sectional analysis of 418Â656 participants in the ⟨scp⟩UK⟨/scp⟩ Biobank study. Diabetic Medicine, 2017, 34, 1120-1128.	2.3	57
479	Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting. Circulation, 2017, 135, 2091-2101.	1.6	403
480	Infant adiposity following a randomised controlled trial of a behavioural intervention in obese pregnancy. International Journal of Obesity, 2017, 41, 1018-1026.	3.4	89
481	Range of Risk Factor Levels. Circulation, 2017, 135, 1522-1531.	1.6	102
482	A genome-wide interaction analysis of tricyclic/tetracyclic antidepressants and RR and QT intervals: a pharmacogenomics study from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium. Journal of Medical Genetics, 2017, 54, 313-323.	3.2	9
483	Study protocol; Thyroid hormone Replacement for Untreated older adults with Subclinical hypothyroidism - a randomised placebo controlled Trial (TRUST). BMC Endocrine Disorders, 2017, 17, 6.	2.2	36
484	Genetic invalidation of Lp-PLA2 as a therapeutic target: Large-scale study of five functional Lp-PLA2-lowering alleles. European Journal of Preventive Cardiology, 2017, 24, 492-504.	1.8	22
485	Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies. Circulation, 2017, 135, 1819-1831.	1.6	67
486	Research digest: prediabetes definitions and diabetes prevention. Lancet Diabetes and Endocrinology,the, 2017, 5, 163.	11.4	1

#	Article	IF	Citations
487	Diabetes, cardiovascular disease, and chronic kidney disease in South Asia: current status and future directions. BMJ: British Medical Journal, 2017, 357, j1420.	2.3	101
488	Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. New England Journal of Medicine, 2017, 376, 1407-1418.	27.0	880
489	Associations of moderate-to-vigorous-intensity physical activity and body mass index with glycated haemoglobin within the general population: a cross-sectional analysis of the 2008 Health Survey for England. BMJ Open, 2017, 7, e014456.	1.9	9
490	Discovery of novel heart rate-associated loci using the Exome Chip. Human Molecular Genetics, 2017, 26, 2346-2363.	2.9	29
491	Left Ventricular Hypertrophy and Cognitive Decline in Old Age. Journal of Alzheimer's Disease, 2017, 58, 275-283.	2.6	17
492	Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect?. British Journal of Pharmacology, 2017, 174, 3898-3913.	5.4	132
493	Causal Associations of Adiposity and Body Fat Distribution With Coronary Heart Disease, Stroke Subtypes, and Type 2 Diabetes Mellitus. Circulation, 2017, 135, 2373-2388.	1.6	304
494	Risk for Incident Heart Failure: A Subjectâ€Level Metaâ€Analysis From the Heart "OMics―in AGEing (HOMAGE) Study. Journal of the American Heart Association, 2017, 6, .	3.7	41
495	Genome-wide meta-analysis of 241,258 adults accounting for smoking behaviour identifies novel loci for obesity traits. Nature Communications, 2017, 8, 14977.	12.8	169
496	PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. Lancet Diabetes and Endocrinology,the, 2017, 5, 97-105.	11.4	298
497	Relationship between outdoor temperature and cardiovascular disease risk factors in older people. European Journal of Preventive Cardiology, 2017, 24, 349-356.	1.8	21
498	Risk of acute kidney injury and survival in patients treated with Metformin: an observational cohort study. BMC Nephrology, 2017 , 18 , 163 .	1.8	63
499	Cardiovascular disease biomarkers are associated with declining renal function in type 2 diabetes. Diabetologia, 2017, 60, 1400-1408.	6.3	14
500	Novel Diabetes Drugs and the Cardiovascular Specialist. Journal of the American College of Cardiology, 2017, 69, 2646-2656.	2.8	75
501	Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. Lancet Diabetes and Endocrinology,the, 2017, 5, 534-543.	11.4	84
502	Authors' reply to Colquhoun and Buchinsky. BMJ: British Medical Journal, 2017, 357, j2447.	2.3	0
503	Visceral adipose tissue activated macrophage content and inflammatory adipokine secretion is higher in pre-eclampsia than in healthy pregnancys. Clinical Science, 2017, 131, 1529-1540.	4.3	26
504	Reverse Causality in Cardiovascular Epidemiological Research. Circulation, 2017, 135, 2369-2372.	1.6	120

#	Article	IF	Citations
505	Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2ÂDiabetes. Journal of the American College of Cardiology, 2017, 70, 704-712.	2.8	142
506	Research digest: topical trials in thyroid disease. Lancet Diabetes and Endocrinology, the, 2017, 5, 497.	11.4	0
507	Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes and Endocrinology, the, 2017, 5, 597-609.	11.4	248
508	Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism. New England Journal of Medicine, 2017, 376, 2534-2544.	27.0	366
509	Research digest: the risks of type 2 diabetes at a young age. Lancet Diabetes and Endocrinology,the, 2017, 5, 331.	11.4	4
510	Screening for familial hypercholesterolaemia in childhood: Avon Longitudinal Study of Parents and Children (ALSPAC). Atherosclerosis, 2017, 260, 47-55.	0.8	21
511	CURRENT SMOKING, MICROVASCULAR PATHOLOGY AND ADVERSE OUTCOME AFTER ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: NEW PATHOPHYSIOLOGICAL INSIGHTS. Journal of the American College of Cardiology, 2017, 69, 175.	2.8	0
512	Screen time is associated with adiposity and insulin resistance in children. Archives of Disease in Childhood, 2017, 102, 612-616.	1.9	52
513	Life Expectancy and Cause-Specific Mortality in Type 2 Diabetes: A Population-Based Cohort Study Quantifying Relationships in Ethnic Subgroups. Diabetes Care, 2017, 40, 338-345.	8.6	121
514	EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Annals of the Rheumatic Diseases, 2017, 76, 17-28.	0.9	918
515	Metformin in adults with type 1 diabetes: <scp>D</scp> esign and methods of <scp>REducing</scp> with <scp>MetfOrmin V</scp> ascular <scp>A</scp> dverse <scp>L</scp> esions (<scp>REMOVAL</scp>): <scp>A</scp> n international multicentre trial. Diabetes, Obesity and Metabolism, 2017, 19, 509-516.	4.4	32
516	Exome-wide association study of plasma lipids in >300,000 individuals. Nature Genetics, 2017, 49, 1758-1766.	21.4	470
517	Associations Between Diabetes and Both Cardiovascular Disease and All-Cause Mortality Are Modified by Grip Strength: Evidence From UK Biobank, a Prospective Population-Based Cohort Study. Diabetes Care, 2017, 40, 1710-1718.	8.6	84
518	Changes in marital quality over 6 years and its association with cardiovascular disease risk factors in men: findings from the ALSPAC prospective cohort study. Journal of Epidemiology and Community Health, 2017, 71, jech-2017-209178.	3.7	16
519	Impact of Selection Bias on Estimation of Subsequent Event Risk. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	28
520	Beating type 2 diabetes into remission. BMJ: British Medical Journal, 2017, 358, j4030.	2.3	51
521	Increasing physical activity in older adults using STARFISH, an interactive smartphone application (app); a pilot study. Journal of Rehabilitation and Assistive Technologies Engineering, 2017, 4, 205566831769623.	0.9	28
522	The potential role and rationale for treatment of heart failure with sodium–glucose coâ€transporter 2 inhibitors. European Journal of Heart Failure, 2017, 19, 1390-1400.	7.1	139

#	Article	IF	Citations
523	Macronutrients and cardiovascular risk in a global context. Lancet Diabetes and Endocrinology,the, 2017, 5, 758-759.	11.4	3
524	Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 1949-1952.	0.9	63
525	Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 877-886.	11.4	245
526	High-Sensitivity Cardiac Troponin Concentration and Risk of First-EverÂCardiovascular Outcomes inA154,052 Participants. Journal of the American College of Cardiology, 2017, 70, 558-568.	2.8	213
527	Dietary fat and total energy intake modifies the association of genetic profile risk score on obesity: evidence from 48 170 UK Biobank participants. International Journal of Obesity, 2017, 41, 1761-1768.	3.4	36
528	Comparison of non-traditional biomarkers, and combinations of biomarkers, for vascular risk prediction in people with type 2 diabetes: The Edinburgh Type 2 Diabetes Study. Atherosclerosis, 2017, 264, 67-73.	0.8	16
529	Metabolic profiling of gestational diabetes in obese women during pregnancy. Diabetologia, 2017, 60, 1903-1912.	6.3	89
530	Research digest: more cardiovascular outcome trials in diabetes. Lancet Diabetes and Endocrinology,the, 2017, 5, 687.	11.4	0
531	Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus. American Journal of Cardiology, 2017, 120, 1521-1527.	1.6	36
532	Sleep Duration and Risk of Type 2 Diabetes. Pediatrics, 2017, 140, .	2.1	48
533	Persistence of Infarct Zone T2 Hyperintensity at 6 Months After Acute ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Imaging, 2017, 10, .	2.6	16
534	Associations of time of day with cardiovascular disease risk factors measured in older men: results from the British Regional Heart Study. BMJ Open, 2017, 7, e018264.	1.9	5
535	Cardiovascular and Mortality Risks in Migrant South Asians with Type 2 Diabetes: Are We Winning the Battle?. Current Diabetes Reports, 2017, 17, 100.	4.2	15
536	Research digest: hypoglycaemia and glucose variability. Lancet Diabetes and Endocrinology,the, 2017, 5, 938.	11.4	2
537	Circulating soluble receptor for advanced glycation end product: Cross-sectional associations with cardiac markers and subclinical vascular disease in older men with and without diabetes. Atherosclerosis, 2017, 264, 36-43.	0.8	16
538	Association of Body Mass Index With Cardiometabolic Disease in the UK Biobank. JAMA Cardiology, 2017, 2, 882.	6.1	181
539	Cardiac Stress and Inflammatory Markers as Predictors of Heart Failure in Patients With Type 2 Diabetes: The ADVANCE Trial. Diabetes Care, 2017, 40, 1203-1209.	8.6	38
540	Investigating the causal effect of smoking on hay fever and asthma: a Mendelian randomization meta-analysis in the CARTA consortium. Scientific Reports, 2017, 7, 2224.	3.3	35

#	Article	IF	CITATIONS
541	Sustained influence of metformin therapy on circulating glucagonâ€like peptideâ€1 levels in individuals with and without type 2 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 356-363.	4.4	47
542	Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients. Clinical Research in Cardiology, 2017, 106, 58-68.	3.3	23
543	Association between active commuting and incident cardiovascular disease, cancer, and mortality: prospective cohort study. BMJ: British Medical Journal, 2017, 357, j1456.	2.3	298
544	Prediction of uncomplicated pregnancies in obese women: a prospective multicentre study. BMC Medicine, 2017, 15, 194.	5.5	15
545	Identification of new susceptibility loci for type 2 diabetes and shared etiological pathways with coronary heart disease. Nature Genetics, 2017, 49, 1450-1457.	21.4	218
546	Customised and Noncustomised Birth Weight Centiles and Prediction of Stillbirth and Infant Mortality and Morbidity: A Cohort Study of 979,912 Term Singleton Pregnancies in Scotland. PLoS Medicine, 2017, 14, e1002228.	8.4	98
547	Comparison of HapMap and 1000 Genomes Reference Panels in a Large-Scale Genome-Wide Association Study. PLoS ONE, 2017, 12, e0167742.	2.5	29
548	Improving pregnancy outcome in obese women: the UK Pregnancies Better Eating and Activity randomised controlled Trial. Programme Grants for Applied Research, 2017, 5, 1-414.	1.0	9
549	Impact of Obesity on Cardiovascular Disease. Endocrinology, 2017, , 1-21.	0.1	1
550	Identifying Cases of Type 2 Diabetes in Heterogeneous Data Sources: Strategy from the EMIF Project. PLoS ONE, 2016, 11, e0160648.	2.5	20
551	Physical Activity Is Prospectively Associated With Adolescent Nonalcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2016, 62, 110-117.	1.8	9
552	Editorial: Lipid Changes With Different Antiinflammatory Regimens in Rheumatoid Arthritis: Developing a Pragmatic Approach to Complex Data. Arthritis and Rheumatology, 2016, 68, 563-565.	5.6	0
553	The incremental prognostic and clinical value of multiple novel biomarkers in heart failure. European Journal of Heart Failure, 2016, 18, 1491-1498.	7.1	54
554	Characteristics of rheumatoid arthritis and its association with major comorbid conditions: cross-sectional study of 502â€649 UK Biobank participants. RMD Open, 2016, 2, e000267.	3.8	55
555	Meta-analysis of genome-wide association studies of HDL cholesterol response to statins. Journal of Medical Genetics, 2016, 53, 835-845.	3.2	28
556	Patterns of weight change after the diagnosis of type 2 diabetes in Scotland and their relationship with glycaemic control, mortality and cardiovascular outcomes: a retrospective cohort study. BMJ Open, 2016, 6, e010836.	1.9	41
557	Remote Zone Extracellular Volume and Left Ventricular Remodeling in Survivors of ST-Elevation Myocardial Infarction. Hypertension, 2016, 68, 385-391.	2.7	44
558	Effect of IL-6 receptor blockade on high-sensitivity troponin T and NT-proBNP in rheumatoid arthritis. Atherosclerosis, 2016, 254, 167-171.	0.8	20

#	Article	IF	CITATIONS
559	Body-mass index and cardiometabolic disease: a Mendelian randomisation study of UK Biobank participants. Lancet, The, 2016, 388, S9.	13.7	3
560	Dietary patterns in obese pregnant women; influence of a behavioral intervention of diet and physical activity in the UPBEAT randomized controlled trial. International Journal of Behavioral Nutrition and Physical Activity, 2016, 13, 124.	4.6	48
561	Screening for diabetes in patients with cardiovascular disease: HbA1c trumps oral glucose tolerance testing. Lancet Diabetes and Endocrinology,the, 2016, 4, 560-562.	11.4	17
562	2016 European Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal, 2016, 37, 2315-2381.	2.2	5,370
563	The changing face of diabetes complications. Lancet Diabetes and Endocrinology, the, 2016, 4, 537-547.	11.4	403
564	Diabetic microvascular complications as simple indicators of risk for cardiovascular outcomes and heart failure. Lancet Diabetes and Endocrinology, the, 2016, 4, 555-556.	11.4	5
565	Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance. JAMA - Journal of the American Medical Association, 2016, 315, 1580.	7.4	420
566	Coding Variation in <i>ANGPTL4,LPL,SVEP1</i> <and 1134-1144.<="" 2016,="" 374,="" coronary="" disease.="" england="" journal="" medicine,="" new="" of="" risk="" td="" the=""><td>27.0</td><td>427</td></and>	27.0	427
567	Temporal Evolution of Myocardial Hemorrhage and Edema in Patients After Acute STâ€Segment Elevation Myocardial Infarction: Pathophysiological Insights and Clinical Implications. Journal of the American Heart Association, 2016, 5, .	3.7	96
568	Increasing physical activity in stroke survivors using STARFISH, an interactive mobile phone application: a pilot study. Topics in Stroke Rehabilitation, 2016, 23, 170-177.	1.9	119
569	Smooth Muscle Enriched Long Noncoding RNA (<i>SMILR</i>) Regulates Cell Proliferation. Circulation, 2016, 133, 2050-2065.	1.6	182
570	Genetic Evidence for a Link Between Favorable Adiposity and Lower Risk of Type 2 Diabetes, Hypertension, and Heart Disease. Diabetes, 2016, 65, 2448-2460.	0.6	122
571	Alzheimer disease genetic risk factor <i>APOE</i> e4 and cognitive abilities in 111,739 UK Biobank participants. Age and Ageing, 2016, 45, 511-517.	1.6	45
572	SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?. Diabetologia, 2016, 59, 1333-1339.	6.3	254
573	Maternal Plasma DHA Levels Increase Prior to 29 Days Post-LH Surge in Women Undergoing Frozen Embryo Transfer: A Prospective, Observational Study of Human Pregnancy. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1745-1753.	3.6	27
574	Cystatin C and Cardiovascular Disease. Journal of the American College of Cardiology, 2016, 68, 934-945.	2.8	109
575	Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. Lancet Diabetes and Endocrinology,the, 2016, 4, 840-849.	11.4	159
576	Association Between Low-Density Lipoprotein Cholesterol–Lowering Genetic Variants and Risk of Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2016, 316, 1383.	7.4	310

#	Article	IF	Citations
577	Research digest: weight loss to prevent and treat diabetes. Lancet Diabetes and Endocrinology,the, 2016, 4, 817.	11.4	3
578	Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes. JAMA Cardiology, 2016, 1, 692.	6.1	233
579	Trends in type 2 diabetes incidence and mortality in Scotland between 2004 and 2013. Diabetologia, 2016, 59, 2106-2113.	6.3	71
580	Fruit, vegetable and vitamin C intakes and plasma vitamin C: crossâ€sectional associations with insulin resistance and glycaemia in 9–10 yearâ€old children. Diabetic Medicine, 2016, 33, 307-315.	2.3	21
581	Relationship Between Blood Pressure Values, Depressive Symptoms, and Cardiovascular Outcomes in Patients With Cardiometabolic Disease. Journal of Clinical Hypertension, 2016, 18, 1027-1035.	2.0	12
582	PCSK9 inhibitors and diabetes risk: a question worth asking?: Table 1. European Heart Journal, 2016, 37, 2990-2992.	2.2	10
583	Cord Blood Adipokines and Lipids and Adolescent Nonalcoholic Fatty Liver Disease. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4661-4668.	3.6	5
584	2016 European Guidelines on cardiovascular disease prevention in clinical practice. Atherosclerosis, 2016, 252, 207-274.	0.8	415
585	Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension. Nature Genetics, 2016, 48, 1151-1161.	21.4	261
586	Copeptin and the risk of incident stroke, CHD and cardiovascular mortality in older men with and without diabetes: The British Regional Heart Study. Diabetologia, 2016, 59, 1904-1912.	6.3	26
587	Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet, The, 2016, 388, 776-786.	13.7	1,793
588	High Serum Immunoglobulin G and M Levels Predict Freedom From Adverse Cardiovascular Events in Hypertension: A Nested Case-Control Substudy of the Anglo-Scandinavian Cardiac Outcomes Trial. EBioMedicine, 2016, 9, 372-380.	6.1	40
589	Adiposity among 132 479 UK Biobank participants; contribution of sugar intake vs other macronutrients. International Journal of Epidemiology, 2016, 46, dyw173.	1.9	21
590	Research digest: NAFLD in the spotlight. Lancet Diabetes and Endocrinology, the, 2016, 4, 735.	11.4	0
591	Study protocol of European Fans in Training (EuroFIT): a four-country randomised controlled trial of a lifestyle program for men delivered in elite football clubs. BMC Public Health, 2016, 16, 598.	2.9	31
592	Glycaemic Effects of Non-statin Lipid-Lowering Therapies. Current Cardiology Reports, 2016, 18, 133.	2.9	4
593	A genomic approach to therapeutic target validation identifies a glucose-lowering <i>GLP1R</i> variant protective for coronary heart disease. Science Translational Medicine, 2016, 8, 341ra76.	12.4	100
594	Research digest: cardiac biomarkers for risk prediction. Lancet Diabetes and Endocrinology,the, 2016, 4, 890.	11.4	2

#	Article	IF	CITATIONS
595	Applying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the future: Table 1 International Journal of Epidemiology, 2016, 45, 1351-1371.	1.9	22
596	115â€Persistence of Infarct Zone Oedema at 6 Months after Acute ST-elevation Myocardial Infarction: Incidence, Pathophysiology and Association with Left Ventricular Remodelling. Heart, 2016, 102, A81.2-A81.	2.9	0
597	114â€Persistence of Haemoglobin Degradation Products within Infarct Scar Tissue after ST-elevation Myocardial Infarction: Incidence, Correlates and Implications for Left Ventricular Remodelling. Heart, 2016, 102, A81.1-A81.	2.9	0
598	2â€Coronary flow reserve and index of microvascular resistance in acute stemi. Heart, 2016, 102, A1.2-A1.	2.9	0
599	Metformin Therapy and Circulating NT-proBNP Levels: The CAMERA Trial. Diabetes Care, 2016, 39, e114-e115.	8.6	2
600	HIGH SERUM IMMUNOGLOBULIN G AND M LEVELS IMPROVE CARDIOVASCULAR RISK DISCRIMINATION IN HYPERTENSION: A NESTED CASE-CONTROL SUBSTUDY OF THE ANGLO-SCANDINAVIAN CARDIAC OUTCOMES TRIAL. Journal of the American College of Cardiology, 2016, 67, 1912.	2.8	0
601	The Diabetes Remission Clinical Trial (DiRECT): protocol for a cluster randomised trial. BMC Family Practice, 2016, 17, 20.	2.9	86
602	Association of maternal diabetes/glycosuria and pre-pregnancy body mass index with offspring indicators of non-alcoholic fatty liver disease. BMC Pediatrics, 2016, 16, 47.	1.7	43
603	2016 European Guidelines on cardiovascular disease prevention in clinical practice. European Journal of Preventive Cardiology, 2016, 23, NP1-NP96.	1.8	683
604	Effect of metformin therapy on circulating amino acids in a randomized trial: the <scp>CAMERA</scp> study. Diabetic Medicine, 2016, 33, 1569-1574.	2.3	32
605	Effects of a beverage rich in (poly)phenols on established and novel risk markers for vascular disease in medically uncomplicated overweight or obese subjects: A four week randomized placebo-controlled trial. Atherosclerosis, 2016, 246, 169-176.	0.8	17
606	Myocardial Hemorrhage After Acute Reperfused ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Imaging, 2016, 9, e004148.	2.6	158
607	Body Mass Index and Risk of Nonalcoholic Fatty Liver Disease: Two Electronic Health Record Prospective Studies. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 945-952.	3.6	160
608	Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2016, 75, 1806-1812.	0.9	119
609	Type 2 diabetes and risk of hospital admission or death for chronic liver diseases. Journal of Hepatology, 2016, 64, 1358-1364.	3.7	67
610	Prognostic significance of infarct core pathology revealed by quantitative non-contrast in comparison with contrast cardiac magnetic resonance imaging in reperfused ST-elevation myocardial infarction survivors. European Heart Journal, 2016, 37, 1044-1059.	2.2	105
611	Risk stratification and treatment effect of statins in secondary cardiovascular prevention in old age: Additive value of N-terminal pro-B-type natriuretic peptide. European Journal of Preventive Cardiology, 2016, 23, 1104-1113.	1.8	4
612	Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. Science, 2016, 351, 1166-1171.	12.6	438

#	Article	IF	Citations
613	Comparison of <scp>PCSK9</scp> Inhibitor Evolocumab vs Ezetimibe in Statinâ€Intolerant Patients: Design of the Goal Achievement After Utilizing an Antiâ€ <scp>PCSK9</scp> Antibody in Statinâ€Intolerant Subjects 3 (<scp>GAUSS</scp> â€3) Trial. Clinical Cardiology, 2016, 39, 137-144.	1.8	32
614	Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data. Lancet Diabetes and Endocrinology, the, 2016, 4, 403-410.	11.4	133
615	Genome-wide meta-analysis uncovers novel loci influencing circulating leptin levels. Nature Communications, 2016, 7, 10494.	12.8	153
616	Accuracy of circulating adiponectin for predicting gestational diabetes: a systematic review and meta-analysis. Diabetologia, 2016, 59, 692-699.	6.3	82
617	High-sensitivity cardiac troponin T is associated with cognitive decline in older adults at high cardiovascular risk. European Journal of Preventive Cardiology, 2016, 23, 1383-1392.	1.8	20
618	Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity, 2016, 40, 1005-1011.	3.4	9
619	Metabolomic Profiling of Statin Use and Genetic Inhibition of HMG-CoA Reductase. Journal of the American College of Cardiology, 2016, 67, 1200-1210.	2.8	173
620	Prediction of Cardiovascular Disease Risk by Cardiac Biomarkers in 2 United Kingdom Cohort Studies. Hypertension, 2016, 67, 309-315.	2.7	33
621	Non-response to (statin) therapy: the importance of distinguishing non-responders from non-adherers in pharmacogenetic studies. European Journal of Clinical Pharmacology, 2016, 72, 431-437.	1.9	27
622	A meta-analysis of 120 246 individuals identifies 18 new loci for fibrinogen concentration. Human Molecular Genetics, 2016, 25, 358-370.	2.9	73
623	Microvascular resistance of the culprit coronary artery in acute ST-elevation myocardial infarction. JCI Insight, 2016, 1, e85768.	5.0	39
624	Life Course Socioeconomic Position: Associations with Cardiac Structure and Function at Age 60-64 Years in the 1946 British Birth Cohort. PLoS ONE, 2016, 11, e0152691.	2.5	9
625	Should Physical Activity Recommendations for South Asian Adults Be Ethnicity-Specific? Evidence from a Cross-Sectional Study of South Asian and White European Men and Women. PLoS ONE, 2016, 11, e0160024.	2.5	50
626	Early Antenatal Prediction of Gestational Diabetes in Obese Women: Development of Prediction Tools for Targeted Intervention. PLoS ONE, 2016, 11, e0167846.	2.5	63
627	Endothelial function measures: not for clinical prime time?. International Journal of Clinical Practice, 2015, 69, 624-625.	1.7	1
628	Associations of mutually exclusive categories of physical activity and sedentary time with markers of cardiometabolic health in English adults: a cross-sectional analysis of the Health Survey for England. BMC Public Health, 2015, 16, 25.	2.9	81
629	Longitudinal Blood Pressure Control, Long-Term Mortality, and Predictive Utility of Serum Liver Enzymes and Bilirubin in Hypertensive Patients. Hypertension, 2015, 66, 37-43.	2.7	28
630	Ethnic differences in associations between fat deposition and incident diabetes and underlying mechanisms: The SABRE study. Obesity, 2015, 23, 699-706.	3.0	48

#	Article	IF	CITATIONS
631	Urinary proteomic biomarkers to predict cardiovascular events. Proteomics - Clinical Applications, 2015, 9, 610-617.	1.6	33
632	Risk assessment and predicting outcomes in patients with depressive symptoms: a review of potential role of peripheral blood based biomarkers. Frontiers in Human Neuroscience, 2015, 9, 18.	2.0	23
633	The Influence of Age and Sex on Genetic Associations with Adult Body Size and Shape: A Large-Scale Genome-Wide Interaction Study. PLoS Genetics, 2015, 11, e1005378.	3 . 5	331
634	Drug-Gene Interactions of Antihypertensive Medications and Risk of Incident Cardiovascular Disease: A Pharmacogenomics Study from the CHARGE Consortium. PLoS ONE, 2015, 10, e0140496.	2.5	15
635	The association of nonalcoholic fatty liver disease with central and peripheral blood pressure in adolescence. Journal of Hypertension, 2015, 33, 546-553.	0.5	11
636	Biological Correlates of Blood Pressure Variability in Elderly at High Risk of Cardiovascular Disease. American Journal of Hypertension, 2015, 28, 469-479.	2.0	12
637	High Blood Pressure and Its Association With Incident Diabetes Over 10 Years in the Korean Genome and Epidemiology Study (KoGES). Diabetes Care, 2015, 38, 1333-1338.	8.6	39
638	Estimated Life Expectancy in a Scottish Cohort With Type 1 Diabetes, 2008-2010. JAMA - Journal of the American Medical Association, 2015, 313, 37.	7.4	454
639	Sex Differences in the Excess Risk of Cardiovascular Diseases Associated with Type 2 Diabetes: Potential Explanations and Clinical Implications. Current Cardiovascular Risk Reports, 2015, 9, 36.	2.0	128
640	Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Annals of the Rheumatic Diseases, 2015, 74, 694-702.	0.9	237
641	Heavier smoking may lead to a relative increase in waist circumference: evidence for a causal relationship from a Mendelian randomisation meta-analysis. The CARTA consortium: TableÂ1. BMJ Open, 2015, 5, e008808.	1.9	53
642	Postnatal testing following gestational diabetes – Authors' reply. Lancet Diabetes and Endocrinology,the, 2015, 3, 762.	11.4	1
643	Mendelian randomisation study for statin treatment – Authors' reply. Lancet, The, 2015, 385, 1946.	13.7	0
644	Genetic studies of body mass index yield new insights for obesity biology. Nature, 2015, 518, 197-206.	27.8	3,823
645	Metabolite Profiling and Cardiovascular Event Risk. Circulation, 2015, 131, 774-785.	1.6	547
646	Diabetes risk and amino acid profiles: cross-sectional and prospective analyses of ethnicity, amino acids and diabetes in a South Asian and European cohort from the SABRE (Southall And Brent) Tj ETQq0 0 0 rgB1	@værlock	R 1 091 £f 50 137
647	Birthweight and risk markers for type 2 diabetes and cardiovascular disease in childhood: the Child Heart and Health Study in England (CHASE). Diabetologia, 2015, 58, 474-484.	6.3	19
648	Blood Lipids and Type 2 Diabetes Risk: Can Genetics Help Untangle the Web?. Diabetes, 2015, 64, 2344-2345.	0.6	7

#	Article	IF	CITATIONS
649	Combined Free Light Chains Are Novel Predictors of Prognosis in Heart Failure. JACC: Heart Failure, 2015, 3, 618-625.	4.1	18
650	Directional dominance on stature and cognition inÂdiverse human populations. Nature, 2015, 523, 459-462.	27.8	173
651	Pathophysiology of LV Remodeling inÂSurvivors of STEMI. JACC: Cardiovascular Imaging, 2015, 8, 779-789.	5.3	116
652	Association of Cardiometabolic Multimorbidity With Mortality. JAMA - Journal of the American Medical Association, 2015, 314, 52.	7.4	624
653	Effect of a behavioural intervention in obese pregnant women (the UPBEAT study): a multicentre, randomised controlled trial. Lancet Diabetes and Endocrinology, the, 2015, 3, 767-777.	11.4	535
654	Debunking the obesity–mortality paradox in RA. Nature Reviews Rheumatology, 2015, 11, 445-446.	8.0	10
655	Preanalytical study of fetuin-A: effect of sample type, processing speed and freeze–thaw cycles. Annals of Clinical Biochemistry, 2015, 52, 165-168.	1.6	0
656	An Evaluation of Risk Factors for Major Adverse Cardiovascular Events During Tocilizumab Therapy. Arthritis and Rheumatology, 2015, 67, 372-380.	5.6	95
657	Postnatal testing following gestational diabetes: time to replace the oral glucose tolerance test?. Lancet Diabetes and Endocrinology,the, 2015, 3, 754-756.	11.4	24
658	Is the adiposityâ€associated <scp><i>FTO</i></scp> gene variant related to allâ€cause mortality independent of adiposity? Metaâ€analysis of data from 169,551 <scp>C</scp> aucasian adults. Obesity Reviews, 2015, 16, 327-340.	6. 5	8
659	A COMPREHENSIVE SAFETY ANALYSIS OF 6026 PATIENTS FROM PHASE 2 AND 3 SHORT AND LONG TERM CLINICAL TRIALS WITH EVOLOCUMAB (AMG 145). Journal of the American College of Cardiology, 2015, 65, A1351.	2.8	8
660	Ethnicity and risk of cardiovascular disease (CVD): 4.8 year follow-up of patients with type 2 diabetes living in Scotland. Diabetologia, 2015, 58, 716-725.	6.3	26
661	Variation in the SLC23A1 gene does not influence cardiometabolic outcomes to the extent expected given its association with l-ascorbic acid. American Journal of Clinical Nutrition, 2015, 101, 202-209.	4.7	13
662	The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. European Heart Journal, 2015, 36, 1536-1546.	2.2	126
663	Does the LDL Receptor Play a Role in the Risk of Developing Type 2 Diabetes?. JAMA - Journal of the American Medical Association, 2015, 313, 1016.	7.4	15
664	Overweight across the life course and adipokines, inflammatory and endothelial markers at age 60–64 years: evidence from the 1946 birth cohort. International Journal of Obesity, 2015, 39, 1010-1018.	3.4	33
665	Classification of reported statin intolerance. Current Opinion in Lipidology, 2015, 26, 65-66.	2.7	3
666	Impact of Maternal Obesity on Perinatal and Childhood Outcomes. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2015, 29, 438-448.	2.8	91

#	Article	IF	Citations
667	Childhood Energy Intake Is Associated with Nonalcoholic Fatty Liver Disease in Adolescents. Journal of Nutrition, 2015, 145, 983-989.	2.9	21
668	Associations Between Prediabetes, by Three Different Diagnostic Criteria, and Incident CVD Differ in South Asians and Europeans. Diabetes Care, 2015, 38, 2325-2332.	8.6	35
669	Copeptin, Insulin Resistance, and Risk of Incident Diabetes in Older Men. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3332-3339.	3.6	65
670	Effect of Smoking on Blood Pressure and Resting Heart Rate. Circulation: Cardiovascular Genetics, 2015, 8, 832-841.	5.1	105
671	Ethnicityâ€specific obesity cutâ€points in the development of Type 2 diabetes – a prospective study including three ethnic groups in the United Kingdom. Diabetic Medicine, 2015, 32, 226-234.	2.3	62
672	Type 2 diabetes in migrant south Asians: mechanisms, mitigation, and management. Lancet Diabetes and Endocrinology,the, 2015, 3, 1004-1016.	11.4	184
673	White Matter Lesion Progression. Stroke, 2015, 46, 3048-3057.	2.0	27
674	Genome of the Netherlands population-specific imputations identify an ABCA6 variant associated with cholesterol levels. Nature Communications, 2015, 6, 6065.	12.8	45
675	SurgiCal Obesity Treatment Study (SCOTS): protocol for a national prospective cohort study of patients undergoing bariatric surgery in Scotland. BMJ Open, 2015, 5, e008106-e008106.	1.9	5
676	SATO105â€Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients with Rheumatoid Arthritis (TRACE RA). Annals of the Rheumatic Diseases, 2015, 74, 688.1-688.	0.9	4
677	End-stage renal disease and survival in people with diabetes: a national database linkage study. QJM - Monthly Journal of the Association of Physicians, 2015, 108, 127-134.	0.5	52
678	Smoking and diabetes risk: building a causal case with clinical implications. Lancet Diabetes and Endocrinology, the, 2015, 3, 918-920.	11.4	12
679	Novel coronary heart disease risk factors at 60–64 years and life course socioeconomic position: The 1946 British birth cohort. Atherosclerosis, 2015, 238, 70-76.	0.8	21
680	Sleep duration and risk markers for type 2 diabetes: a cross-sectional study in children aged 9–10 years. Lancet, The, 2015, 386, S4.	13.7	1
681	Psoriasis, psoriatic arthritis and cardiovascular risk: are we closer to a clinical recommendation?. Annals of the Rheumatic Diseases, 2015, 74, 321-322.	0.9	20
682	Reducing cardiovascular risk in type 2 diabetes mellitus. Medicine, 2015, 43, 7-12.	0.4	1
683	HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet, The, 2015, 385, 351-361.	13.7	562
684	An Investigation of Two-Dimensional Ultrasound Carotid Plaque Presence and Intima Media Thickness in Middle-Aged South Asian and European Men Living in the United Kingdom. PLoS ONE, 2015, 10, e0123317.	2.5	9

#	Article	IF	CITATIONS
685	Effects of Tumour Necrosis Factor Antagonists on Insulin Sensitivity/Resistance in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. PLoS ONE, 2015, 10, e0128889.	2.5	63
686	Prevalence of cardiometabolic risk factors and metabolic syndrome in obese Kuwaiti adolescents. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2014, 7, 505.	2.4	10
687	Cognitive and Kidney Function: Results from a British Birth Cohort Reaching Retirement Age. PLoS ONE, 2014, 9, e86743.	2.5	18
688	The Relation of Rapid Changes in Obesity Measures to Lipid Profile - Insights from a Nationwide Metabolic Health Survey in 444 Polish Cities. PLoS ONE, 2014, 9, e86837.	2.5	15
689	No Evidence for Genome-Wide Interactions on Plasma Fibrinogen by Smoking, Alcohol Consumption and Body Mass Index: Results from Meta-Analyses of 80,607 Subjects. PLoS ONE, 2014, 9, e111156.	2.5	8
690	OP19â€Fruit, vegetable, vitamin C intakes and plasma vitamin C: associations with insulin resistance in UK primary school children. Journal of Epidemiology and Community Health, 2014, 68, A12.2-A13.	3.7	0
691	Advances in managing type 2 diabetes: challenging old paradigms and developing new ones. F1000prime Reports, 2014, 6, 42.	5.9	9
692	The Value of N-Terminal Pro–B-Type Natriuretic Peptide in Determining Antihypertensive Benefit. Hypertension, 2014, 63, 507-513.	2.7	25
693	Culturally adapting the prevention of diabetes and obesity in South Asians (PODOSA) trial. Health Promotion International, 2014, 29, 768-779.	1.8	35
694	Response to Effect of Serum Chloride on Mortality in Hypertensive Patients. Hypertension, 2014, 63, e15.	2.7	1
695	A dysglycaemic effect of statins in diabetes: relevance to clinical practice?. Diabetologia, 2014, 57, 2433-2435.	6.3	17
696	Regular Breakfast Consumption and Type 2 Diabetes Risk Markers in 9- to 10-Year-Old Children in the Child Heart and Health Study in England (CHASE): A Cross-Sectional Analysis. PLoS Medicine, 2014, 11, e1001703.	8.4	47
697	Stress Hyperglycaemia in Hospitalised Patients and Their 3-Year Risk of Diabetes: A Scottish Retrospective Cohort Study. PLoS Medicine, 2014, 11, e1001708.	8.4	44
698	Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nature Communications, 2014, 5, 5068.	12.8	216
699	Response to Comment on Hillis et al. The Relative and Combined Ability of High-Sensitivity Cardiac Troponin T and N-Terminal Pro-B-Type Natriuretic Peptide to Predict Cardiovascular Events and Death in Patients With Type 2 Diabetes. Diabetes Care 2014;37:295–303. Diabetes Care, 2014, 37, e154-e154.	8.6	1
700	Comment on Shah et al. Cardiovascular Complications and Mortality After Diabetes Diagnosis for South Asian and Chinese Patients: A Population-Based Cohort Study. Diabetes Care 2013;36:2670–2676. Diabetes Care, 2014, 37, e78-e79.	8.6	2
701	Stratification by Smoking Status Reveals an Association of CHRNA5-A3-B4 Genotype with Body Mass Index in Never Smokers. PLoS Genetics, 2014, 10, e1004799.	3.5	45
702	Response to †Interleukin-6 signal transduction and its role in hepatic lipid metabolic disorders' by Hassan et al Cytokine, 2014, 70, 198.	3.2	0

#	Article	IF	Citations
703	Genome-Wide Association Study for Circulating Tissue Plasminogen Activator Levels and Functional Follow-Up Implicates Endothelial <i>STXBP5</i> and <i>STX2</i> Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1093-1101.	2.4	43
704	Associations of childhood 25-hydroxyvitamin D ₂ and D ₃ and cardiovascular risk factors in adolescence: prospective findings from the Avon Longitudinal Study of Parents and Children. European Journal of Preventive Cardiology, 2014, 21, 281-290.	1.8	24
705	OP80â€Birth weight and emerging type 2 diabetes risk in UK children of South Asian, black African-Caribbean and white European origin – Child Heart and Health Study in England (CHASE). Journal of Epidemiology and Community Health, 2014, 68, A39.3-A40.	3.7	0
706	Vitamin D genes and mortality. BMJ, The, 2014, 349, g6599-g6599.	6.0	6
707	Prediction of gestational diabetes in obese pregnant women from the UK Pregnancies Better Eating and Activity (UPBEAT) pilot trial. Diabetic Medicine, 2014, 31, 963-970.	2.3	36
708	Elevated Parathyroid Hormone, But Not Vitamin D Deficiency, Is Associated With Increased Risk of Heart Failure in Older Men With and Without Cardiovascular Disease. Circulation: Heart Failure, 2014, 7, 732-739.	3.9	75
709	Nâ€ŧerminal pro–brain natriuretic peptide and cognitive decline in older adults at high cardiovascular risk. Annals of Neurology, 2014, 76, 213-222.	5.3	18
710	Factors associated with statin treatment for the primary prevention of cardiovascular disease in people within 2Âyears following diagnosis of diabetes in Scotland, 2006–2008. Diabetic Medicine, 2014, 31, 640-646.	2.3	12
711	Homocysteine Levels and Treatment Effect in the Prospective Study of Pravastatin in the Elderly at Risk. Journal of the American Geriatrics Society, 2014, 62, 213-221.	2.6	24
712	Nâ€terminal pro brain natriuretic peptide but not copeptin improves prediction of heart failure over other routine clinical risk parameters in older men with and without cardiovascular disease: populationâ€based study. European Journal of Heart Failure, 2014, 16, 25-32.	7.1	46
713	Assessing Risk Prediction Models Using Individual Participant Data From Multiple Studies. American Journal of Epidemiology, 2014, 179, 621-632.	3.4	47
714	Glycated Hemoglobin Measurement and Prediction of Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2014, 311, 1225.	7.4	179
715	N-terminal pro-brain natriuretic peptide and risk of cardiovascular events in older patients with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetologia, 2014, 57, 2505-2512.	6.3	16
716	Pregnancy glycaemia and cord-blood levels of insulin and leptin in Pakistani and white British mother–offspring pairs: findings from a prospective pregnancy cohort. Diabetologia, 2014, 57, 2492-2500.	6.3	41
717	Hyperglycemia Has a Greater Impact on Left Ventricle Function in South Asians Than in Europeans. Diabetes Care, 2014, 37, 1124-1131.	8.6	18
718	Ethnic-Specific Obesity Cutoffs for Diabetes Risk: Cross-sectional Study of 490,288 UK Biobank Participants. Diabetes Care, 2014, 37, 2500-2507.	8.6	168
719	The Association of Rate of Weight Gain During Early Adulthood With the Prevalence of Subclinical Coronary Artery Disease in Recently Diagnosed Type 2 Diabetes: The MAXWEL-CAD Study. Diabetes Care, 2014, 37, 2491-2499.	8.6	10
720	Do ethnic differences in cord blood leptin levels differ by birthweight category? Findings from the Born in Bradford cohort study. International Journal of Epidemiology, 2014, 43, 249-254.	1.9	22

#	Article	IF	Citations
721	Change in levels of physical activity after diagnosis of type 2 diabetes: an observational analysis from the NAVIGATOR study. Diabetes, Obesity and Metabolism, 2014, 16, 1265-1268.	4.4	2
722	The obesity paradox in men with coronary heart disease and heart failure: The role of muscle mass and leptin. International Journal of Cardiology, 2014, 171, 49-55.	1.7	65
723	Effect of a lifestyle intervention on weight change in south Asian individuals in the UK at high risk of type 2 diabetes: a family-cluster randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2014, 2, 218-227.	11.4	110
724	An assessment by the Statin Diabetes Safety Task Force: 2014 update. Journal of Clinical Lipidology, 2014, 8, S17-S29.	1.5	102
725	GuÃa de práctica clÃnica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes. Revista Espanola De Cardiologia, 2014, 67, 136.e1-136.e56.	1.2	15
726	Nonalcoholic Fatty Liver Disease, Liver Fibrosis, and Cardiometabolic Risk Factors in Adolescence: A Cross-Sectional Study of 1874 General Population Adolescents. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E410-E417.	3.6	57
727	Thromboembolic and cardiovascular risk in rheumatoid arthritis: role of the haemostatic system. Annals of the Rheumatic Diseases, 2014, 73, 954-957.	0.9	68
728	Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabetes and Endocrinology, the, 2014, 2, 116-124.	11.4	157
729	Association between cardiovascular risk factors and concurrent depressive symptoms in cardiometabolic disease: a cross-sectional study. Lancet, The, 2014, 384, S40.	13.7	3
730	Contrasting associations of insulin resistance with diabetes, cardiovascular disease and all-cause mortality in the elderly: PROSPER long-term follow-up. Diabetologia, 2014, 57, 2513-2520.	6.3	30
731	In Preeclampsia, Maternal Third Trimester Subcutaneous Adipocyte Lipolysis Is More Resistant to Suppression by Insulin Than in Healthy Pregnancy. Hypertension, 2014, 63, 1094-1101.	2.7	14
732	The emergence of proton nuclear magnetic resonance metabolomics in the cardiovascular arena as viewed from a clinical perspective. Atherosclerosis, 2014, 237, 287-300.	0.8	57
733	How low to aim in rheumatoid arthritis? Learning from other disciplines. Annals of the Rheumatic Diseases, 2014, 73, 480-482.	0.9	9
734	Infant Body Composition and Adipokine Concentrations in Relation to Maternal Gestational Weight Gain. Diabetes Care, 2014, 37, 1432-1438.	8.6	14
735	Non-alcoholic fatty liver disease. BMJ, The, 2014, 349, g4596-g4596.	6.0	253
736	Genome-wide association meta-analysis of human longevity identifies a novel locus conferring survival beyond 90 years of age. Human Molecular Genetics, 2014, 23, 4420-4432.	2.9	227
737	Type 2 diabetes as a disease of ectopic fat?. BMC Medicine, 2014, 12, 123.	5.5	158
738	Response to: †The influence of inflammation in the development of subclinical atherosclerosis in psoriatic arthritis' by González-Gayet al. Annals of the Rheumatic Diseases, 2014, 73, e28-e28.	0.9	0

#	Article	IF	CITATIONS
739	Markers of endothelial dysfunction and cerebral blood flow in older adults. Neurobiology of Aging, 2014, 35, 373-377.	3.1	32
740	The Relative and Combined Ability of High-Sensitivity Cardiac Troponin T and N-Terminal Pro-B-Type Natriuretic Peptide to Predict Cardiovascular Events and Death in Patients With Type 2 Diabetes. Diabetes Care, 2014, 37, 295-303.	8.6	65
741	Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. BMJ, The, 2014, 349, g4164-g4164.	6.0	528
742	A complex intervention to improve pregnancy outcome in obese women; the UPBEAT randomised controlled trial. BMC Pregnancy and Childbirth, 2014, 14, 74.	2.4	74
743	Do Cardiac Biomarkers NT-proBNP and hsTnT Predict Microvascular Events in Patients With Type 2 Diabetes? Results From the ADVANCE Trial. Diabetes Care, 2014, 37, 2202-2210.	8.6	32
744	N-terminal pro-brain-type natriuretic peptide (NT-pro-BNP) and mortality risk in early inflammatory polyarthritis: results from the Norfolk Arthritis Registry (NOAR). Annals of the Rheumatic Diseases, 2014, 73, 684-690.	0.9	31
745	Analysis and modelling of cholesterol and high-density lipoprotein cholesterol changes across the range of C-reactive protein levels in clinical practice as an aid to better understanding of inflammation–lipid interactions. Annals of the Rheumatic Diseases, 2014, 73, 1495-1499.	0.9	26
746	Weight trajectories through infancy and childhood and risk of non-alcoholic fatty liver disease in adolescence: The ALSPAC study. Journal of Hepatology, 2014, 61, 626-632.	3.7	107
747	In search for genetic determinants of clinically meaningful differential cardiovascular event reduction by pravastatin in the PHArmacogenetic study of Statins in the Elderly at risk (PHASE)/PROSPER study. Atherosclerosis, 2014, 235, 58-64.	0.8	8
748	Lessons from SAVOR and EXAMINE: Some important answers, but many open questions. Journal of Diabetes and Its Complications, 2014, 28, 430-433.	2.3	13
749	Treatment of severe hypertriglyceridaemia. Lancet Diabetes and Endocrinology,the, 2014, 2, 860.	11.4	1
750	Fruit juice: just another sugary drink?. Lancet Diabetes and Endocrinology, the, 2014, 2, 444-446.	11.4	36
751	Lifelong patterns of BMI and cardiovascular phenotype in individuals aged 60–64 years in the 1946 British birth cohort study: an epidemiological study. Lancet Diabetes and Endocrinology,the, 2014, 2, 648-654.	11.4	76
752	The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice. Atherosclerosis Supplements, 2014, 15, 1-15.	1.2	83
753	Drug–gene interactions and the search for missing heritability: a cross-sectional pharmacogenomics study of the QT interval. Pharmacogenomics Journal, 2014, 14, 6-13.	2.0	28
754	Understanding experiences of participating in a weight loss lifestyle intervention trial: a qualitative evaluation of South Asians at high risk of diabetes. BMJ Open, 2014, 4, e004736-e004736.	1.9	31
755	P4-021: ASSOCIATION OF BLOOD PRESSURE LOWERING MEDICATION WITH VISIT-TO-VISIT BLOOD PRESSURE VARIABILITY AND COGNITIVE FUNCTION IN OLD AGE. , 2014, 10, P790-P791.		O
756	Body Mass Index and Waist Circumference Cut-Points in Multi-Ethnic Populations from the UK and India: The ADDITION-Leicester, Jaipur Heart Watch and New Delhi Cross-Sectional Studies. PLoS ONE, 2014, 9, e90813.	2.5	39

#	Article	IF	CITATIONS
757	Developing a complex intervention for diet and activity behaviour change in obese pregnant women (the UPBEAT trial); assessment of behavioural change and process evaluation in a pilot randomised controlled trial. BMC Pregnancy and Childbirth, 2013, 13, 148.	2.4	112
758	Lower cardiorespiratory fitness contributes to increased insulin resistance and fasting glycaemia in middle-aged South Asian compared with European men living in the UK. Diabetologia, 2013, 56, 2238-2249.	6.3	54
759	Type 2 diabetes, socioeconomic status and risk of cancer in Scotland 2001–2007. Diabetologia, 2013, 56, 1712-1715.	6.3	12
760	Insulin resistance in type 1 diabetes: what is â€~double diabetes' and what are the risks?. Diabetologia, 2013, 56, 1462-1470.	6.3	172
761	Socioeconomic Status and the Cerebellar Grey Matter Volume. Data from a Well-Characterised Population Sample. Cerebellum, 2013, 12, 882-891.	2.5	27
762	Cardio-metabolic risk factors and cortical thickness in a neurologically healthy male population: Results from the psychological, social and biological determinants of ill health (pSoBid) study. Neurolmage: Clinical, 2013, 2, 646-657.	2.7	27
763	Serum Chloride Is an Independent Predictor of Mortality in Hypertensive Patients. Hypertension, 2013, 62, 836-843.	2.7	67
764	Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Annals of the Rheumatic Diseases, 2013, 72, 211-216.	0.9	224
765	Secretory Phospholipase A2-IIA and Cardiovascular Disease. Journal of the American College of Cardiology, 2013, 62, 1966-1976.	2.8	115
766	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2013, 34, 3035-3087.	2.2	1,758
767	Clinical and Subclinical Macrovascular Disease as Predictors of Cognitive Decline in Older Patients With Type 2 Diabetes. Diabetes Care, 2013, 36, 2779-2786.	8.6	65
768	Reducing cardiovascular disease risk in type 2 diabetes: is the focus on glycaemia warranted?. Diabetes, Obesity and Metabolism, 2013, 15, 387-391.	4.4	14
769	Resting heart rate and incident heart failure and cardiovascular mortality in older adults: role of inflammation and endothelial dysfunction: the PROSPER study. European Journal of Heart Failure, 2013, 15, 581-588.	7.1	57
770	The Relationship Between Metabolic Risk Factors and Incident Cardiovascular Disease in Europeans, South Asians, and African Caribbeans. Journal of the American College of Cardiology, 2013, 61, 1777-1786.	2.8	237
771	Early-Life Overweight Trajectory and CKD in the 1946 British Birth Cohort Study. American Journal of Kidney Diseases, 2013, 62, 276-284.	1.9	44
772	Evaluation of C-Reactive Protein Before and On-Treatment as a Predictor of Benefit of Atorvastatin. Journal of the American College of Cardiology, 2013, 62, 717-729.	2.8	28
773	Gender aspects in type 2 diabetes mellitus and cardiometabolic risk. Best Practice and Research in Clinical Endocrinology and Metabolism, 2013, 27, 501-507.	4.7	132
774	Body weight and mortality in type 2 diabetes: Weighing up the evidence. Diabetes and Metabolism, 2013, 39, 287-288.	2.9	2

#	Article	IF	Citations
775	Epidemiological evidence against a role for C-reactive protein causing leptin resistance. European Journal of Endocrinology, 2013, 168, 101-106.	3.7	5
776	Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nature Reviews Rheumatology, 2013, 9, 513-523.	8.0	212
777	Revisiting the links between glycaemia, diabetes and cardiovascular disease. Diabetologia, 2013, 56, 686-695.	6.3	140
778	Circulating IL-6 concentrations and associated anthropometric and metabolic parameters in South Asian men and women in comparison to European whites. Cytokine, 2013, 61, 29-32.	3.2	15
779	Association between Younger Age When First Overweight and Increased Risk for CKD. Journal of the American Society of Nephrology: JASN, 2013, 24, 813-821.	6.1	56
780	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Annals of the Rheumatic Diseases, 2013, 72, 482-492.	0.9	102
781	Distinct Relationships of Intramuscular and Subcutaneous Fat With Cortical Bone: Findings From a Cross-Sectional Study of Young Adult Males and Females. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1041-E1049.	3.6	19
782	UK-born Pakistani-origin infants are relatively more adipose than white British infants: findings from 8704 mother-offspring pairs in the Born-in-Bradford prospective birth cohort. Journal of Epidemiology and Community Health, 2013, 67, 544-551.	3.7	43
783	A Meta-Analysis of Thyroid-Related Traits Reveals Novel Loci and Gender-Specific Differences in the Regulation of Thyroid Function. PLoS Genetics, 2013, 9, e1003266.	3.5	194
784	Prenatal Exposures and Anti-M \tilde{A}^{1} /4llerian Hormone in Female Adolescents. American Journal of Epidemiology, 2013, 178, 1414-1423.	3.4	23
785	Adiposity, Adipokines, and Risk of Incident Stroke in Older Men. Stroke, 2013, 44, 3-8.	2.0	33
786	Socioeconomic Deprivation and Cortical Morphology. Psychosomatic Medicine, 2013, 75, 616-623.	2.0	44
787	Lipid metabolism. Current Opinion in Lipidology, 2013, 24, 101-102.	2.7	1
788	Choice of medical therapy to lower triglycerides in those at risk of pancreatitis. Current Opinion in Lipidology, 2013, 24, 532-533.	2.7	2
789	Hypertensive Disorders of Pregnancy and Cardiometabolic Health in Adolescent Offspring. Hypertension, 2013, 62, 614-620.	2.7	125
790	Circulating interleukinâ€6 concentration and cognitive decline in old age: the <scp>PROSPER</scp> study. Journal of Internal Medicine, 2013, 274, 77-85.	6.0	95
791	Insulin Resistance and Truncal Obesity as Important Determinants of the Greater Incidence of Diabetes in Indian Asians and African Caribbeans Compared With Europeans. Diabetes Care, 2013, 36, 383-393.	8.6	136
792	Multiethnic Meta-Analysis of Genome-Wide Association Studies in >100 000 Subjects Identifies 23 Fibrinogen-Associated Loci but No Strong Evidence of a Causal Association Between Circulating Fibrinogen and Cardiovascular Disease. Circulation, 2013, 128, 1310-1324.	1.6	128

#	Article	IF	Citations
793	External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants?. Diabetic Medicine, 2013, 30, 300-308.	2.3	97
794	Alkaline Phosphatase, Serum Phosphate, and Incident Cardiovascular Disease and Total Mortality in Older Men. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1070-1076.	2.4	104
795	Testing the inflammation–insulin resistance link in clinical trials. Nature Reviews Rheumatology, 2013, 9, 702-703.	8.0	1
796	Association Between BMI Measured Within a Year After Diagnosis of Type 2 Diabetes and Mortality. Diabetes Care, 2013, 36, 887-893.	8.6	120
797	Influence of Adiposity on Insulin Resistance and Glycemia Markers Among U.K. Children of South Asian, Black African-Caribbean, and White European Origin. Diabetes Care, 2013, 36, 1712-1719.	8.6	66
798	Low birth weight, later renal function, and the roles of adulthood blood pressure, diabetes, and obesity in a British birth cohort. Kidney International, 2013, 84, 1262-1270.	5.2	53
799	N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: results from 15-year follow-up of WOSCOPS. European Heart Journal, 2013, 34, 443-450.	2.2	46
800	'N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: results from 15-year follow-up of WOSCOPS' [Eur Heart J (2013); 34(6):443-450]. European Heart Journal, 2013, 34, 1094-1094.	2.2	0
801	PCSK9 SNP rs11591147 is associated with low cholesterol levels but not with cognitive performance or noncardiovascular clinical events in an elderly population. Journal of Lipid Research, 2013, 54, 561-566.	4.2	23
802	FRIO142â€Aggressive dmard therapy elevates hdl-cholesterol and lowers the atherogenic index in the taser study. Annals of the Rheumatic Diseases, 2013, 72, A418.1-A418.	0.9	0
803	Non-Homologous End-Joining Pathway Associated with Occurrence of Myocardial Infarction: Gene Set Analysis of Genome-Wide Association Study Data. PLoS ONE, 2013, 8, e56262.	2.5	17
804	Long-Term Effects of Statin Treatment in Elderly People: Extended Follow-Up of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). PLoS ONE, 2013, 8, e72642.	2.5	41
805	Personality, Socio-Economic Status and Inflammation: Cross-Sectional, Population-Based Study. PLoS ONE, 2013, 8, e58256.	2.5	37
806	Anti-MÃ1/4llerian Hormone Is Not Associated with Cardiometabolic Risk Factors in Adolescent Females. PLoS ONE, 2013, 8, e64510.	2.5	27
807	Should Physical Activity Recommendations Be Ethnicity-Specific? Evidence from a Cross-Sectional Study of South Asian and European Men. PLoS ONE, 2013, 8, e82568.	2.5	31
808	Ethnic Differences in Glycaemic Control in People with Type 2 Diabetes Mellitus Living in Scotland. PLoS ONE, 2013, 8, e83292.	2.5	30
809	Subclinical Thyroid Dysfunction and the Risk of Heart Failure in Older Persons at High Cardiovascular Risk. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 852-861.	3.6	178
810	Risk of Cardiovascular Disease and Total Mortality in Adults with Type 1 Diabetes: Scottish Registry Linkage Study. PLoS Medicine, 2012, 9, e1001321.	8.4	270

#	Article	IF	Citations
811	Novel Loci for Adiponectin Levels and Their Influence on Type 2 Diabetes and Metabolic Traits: A Multi-Ethnic Meta-Analysis of 45,891 Individuals. PLoS Genetics, 2012, 8, e1002607.	3.5	419
812	Î ³ -Glutamyltransferase, Hepatic Enzymes, and Risk of Incident Heart Failure in Older Men. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 830-835.	2.4	62
813	The Use of Blood Biomarkers to Predict Poor Outcome After Acute Transient Ischemic Attack or Ischemic Stroke. Stroke, 2012, 43, 86-91.	2.0	111
814	Associations of Gestational Diabetes, Existing Diabetes, and Glycosuria With Offspring Obesity and Cardiometabolic Outcomes. Diabetes Care, 2012, 35, 63-71.	8.6	64
815	Lipid-Modifying Therapies and Risk of Pancreatitis. JAMA - Journal of the American Medical Association, 2012, 308, 804.	7.4	140
816	Associations of Pregnancy Complications With Calculated Cardiovascular Disease Risk and Cardiovascular Risk Factors in Middle Age. Circulation, 2012, 125, 1367-1380.	1.6	336
817	Cardiovascular biomarkers and vascular function during childhood in the offspring of mothers with hypertensive disorders of pregnancy: findings from the Avon Longitudinal Study of Parents and Children. European Heart Journal, 2012, 33, 335-345.	2.2	127
818	C-Reactive Protein, Fibrinogen, and Cardiovascular Disease Prediction. New England Journal of Medicine, 2012, 367, 1310-1320.	27.0	909
819	Statins and new-onset diabetesâ€"the important questions. Nature Reviews Cardiology, 2012, 9, 190-192.	13.7	21
820	The Association of Fasting Insulin, Glucose, and Lipids with Bone Mass in Adolescents: Findings from a Cross-Sectional Study. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2068-2076.	3.6	35
821	Cardiovascular and metabolic risks in psoriasis and psoriatic arthritis: pragmatic clinical management based on available evidence: Table 1. Annals of the Rheumatic Diseases, 2012, 71, 480-483.	0.9	39
822	Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nature Genetics, 2012, 44, 991-1005.	21.4	746
823	Plasmacytoid Dendritic Cells Play a Key Role in Promoting Atherosclerosis in Apolipoprotein E–Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 2569-2579.	2.4	101
824	Reduced Incidence of Lower-Extremity Amputations in People With Diabetes in Scotland. Diabetes Care, 2012, 35, 2588-2590.	8.6	95
825	Genetic variation in the 15q25 nicotinic acetylcholine receptor gene cluster (CHRNA5–CHRNA3–CHRNB4) interacts with maternal self-reported smoking status during pregnancy to influence birth weight. Human Molecular Genetics, 2012, 21, 5344-5358.	2.9	62
826	Hot flushes, vascular reactivity and the role of the α-adrenergic system. Climacteric, 2012, 15, 332-338.	2.4	18
827	Hypermethylation at loci sensitive to the prenatal environment is associated with increased incidence of myocardial infarction. International Journal of Epidemiology, 2012, 41, 106-115.	1.9	69
828	Blood Pressure Variability and Cardiovascular Risk in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). PLoS ONE, 2012, 7, e52438.	2.5	63

#	Article	IF	Citations
829	Ethnic Differences in Carotid Intima-Media Thickness Between UK Children of Black African-Caribbean and White European Origin. Stroke, 2012, 43, 1747-1754.	2.0	31
830	Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial. European Heart Journal, 2012, 33, 486-494.	2.2	48
831	Increasing requests for vitamin D measurement: costly, confusing, and without credibility. Lancet, The, 2012, 379, 95-96.	13.7	186
832	The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet, The, 2012, 379, 1214-1224.	13.7	886
833	Vitamin D testing – Authors' reply. Lancet, The, 2012, 379, 1700-1701.	13.7	0
834	Leptin Levels and Depressive Symptoms in People With Type 2 Diabetes. Psychosomatic Medicine, 2012, 74, 39-45.	2.0	23
835	Statins are diabetogenic – Myth or reality?. Atherosclerosis Supplements, 2012, 13, 1-10.	1.2	88
836	25-Hydroxyvitamin D is lower in deprived groups, but is not associated with carotid intima media thickness or plaques: Results from pSoBid. Atherosclerosis, 2012, 223, 437-441.	0.8	21
837	Eplerenone and newâ€onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASISâ€HF). European Journal of Heart Failure, 2012, 14, 909-915.	7.1	59
838	Maternal adiposityâ€"a determinant of perinatal and offspring outcomes?. Nature Reviews Endocrinology, 2012, 8, 679-688.	9.6	159
839	Is it important to measure or reduce C-reactive protein in people at risk of cardiovascular disease?. European Heart Journal, 2012, 33, 2258-2264.	2.2	14
840	Low vitamin D levels are related to left ventricular concentric remodelling in men of different ethnic groups with varying cardiovascular risk. International Journal of Cardiology, 2012, 158, 444-447.	1.7	6
841	Circulating 25OHD, Dietary Vitamin D, PTH, and Calcium Associations with Incident Cardiovascular Disease and Mortality: The MIDSPAN Family Study. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4578-4587.	3.6	53
842	Early life socioeconomic status, chronic physiological stress and hippocampal N-acetyl aspartate concentrations. Behavioural Brain Research, 2012, 235, 225-230.	2.2	20
843	Childhood Obesity and Vascular Phenotypes. Journal of the American College of Cardiology, 2012, 60, 2643-2650.	2.8	117
844	Reduction of ethnic inequalities in birthweight: a public health paradox. Lancet, The, 2012, 380, S78.	13.7	0
845	Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. Diabetologia, 2012, 55, 2929-2937.	6.3	128
846	Area-based socioeconomic status, type 2 diabetes and cardiovascular mortality in Scotland. Diabetologia, 2012, 55, 2938-2945.	6.3	45

#	Article	IF	Citations
847	Diabetic retinopathy at diagnosis of type 2 diabetes in Scotland. Diabetologia, 2012, 55, 2335-2342.	6.3	82
848	The effect of deprivation and HbA1c on admission to hospital for diabetic ketoacidosis in type 1 diabetes. Diabetologia, 2012, 55, 2356-2360.	6.3	39
849	Socio-Economic Position and Type 2 Diabetes Risk Factors: Patterns in UK Children of South Asian, Black African-Caribbean and White European Origin. PLoS ONE, 2012, 7, e32619.	2.5	35
850	A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nature Genetics, 2012, 44, 659-669.	21.4	762
851	The association between insulin levels and cortical bone: Findings from a cross-sectional analysis of pQCT parameters in adolescents. Journal of Bone and Mineral Research, 2012, 27, 610-618.	2.8	40
852	Association Between Genetic Variants on Chromosome 15q25 Locus and Objective Measures of Tobacco Exposure. Journal of the National Cancer Institute, 2012, 104, 740-748.	6.3	198
853	HbA1c in type 2 diabetes diagnostic criteria: addressing the right questions to move the field forwards. Diabetologia, 2012, 55, 1564-1567.	6.3	19
854	Biomarkers for diabetes prediction, pathogenesis or pharmacotherapy guidance? Past, present and future possibilities. Diabetic Medicine, 2012, 29, 5-13.	2.3	42
855	Implementation of proteomic biomarkers: making it work. European Journal of Clinical Investigation, 2012, 42, 1027-1036.	3.4	151
856	Association of Nâ€terminal proâ€"brain natriuretic peptide with cardiac disease, but not with vascular disease, in systemic lupus erythematosus. Arthritis and Rheumatism, 2012, 64, 316-317.	6.7	7
857	Do women exhibit greater differences in established and novel risk factors between diabetes and non-diabetes than men? The British Regional Heart Study and British Women's Heart Health Study. Diabetologia, 2012, 55, 80-87.	6.3	181
858	Intergenerational change and familial aggregation of body mass index. European Journal of Epidemiology, 2012, 27, 53-61.	5.7	28
859	Genome-Wide Study of Gene Variants Associated with Differential Cardiovascular Event Reduction by Pravastatin Therapy. PLoS ONE, 2012, 7, e38240.	2.5	30
860	Association of N-Terminal Pro-Brain Natriuretic Peptide with Cognitive Function and Depression in Elderly People with Type 2 Diabetes. PLoS ONE, 2012, 7, e44569.	2.5	25
861	Soluble ST2 Associates with Diabetes but Not Established Cardiovascular Risk Factors: A New Inflammatory Pathway of Relevance to Diabetes?. PLoS ONE, 2012, 7, e47830.	2.5	56
862	The Effects of Tumor Necrosis Factor Inhibitors on Cardiovascular Risk in Rheumatoid Arthritis. Current Pharmaceutical Design, 2012, 18, 1502-1511.	1.9	42
863	A Pilot Study on the Effect of Short-Term Consumption of a Polyphenol Rich Drink on Biomarkers of Coronary Artery Disease Defined by Urinary Proteomics. Journal of Agricultural and Food Chemistry, 2011, 59, 12850-12857.	5.2	32
864	IQ, Educational Attainment, Memory and Plasma Lipids: Associations with Apolipoprotein E Genotype in 5995 Children. Biological Psychiatry, 2011, 70, 152-158.	1.3	37

#	Article	IF	Citations
865	N-Terminal Pro-Brain Natriuretic Peptide Is a More Useful Predictor of Cardiovascular Disease Risk Than C-Reactive Protein in Older Men With and Without Pre-Existing Cardiovascular Disease. Journal of the American College of Cardiology, 2011, 58, 56-64.	2.8	64
866	Obesity and Risk of Incident Heart Failure in Older Men With and Without Pre-Existing Coronary Heart Disease. Journal of the American College of Cardiology, 2011, 58, 1870-1877.	2.8	96
867	Type 2 diabetes and cardiovascular disease in South Asians. Primary Care Diabetes, 2011, 5, 45-56.	1.8	177
868	Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death. New England Journal of Medicine, 2011, 364, 829-841.	27.0	2,182
869	First-Trimester Circulating 25-Hydroxyvitamin D Levels and Development of Gestational Diabetes Mellitus. Diabetes Care, 2011, 34, 1091-1093.	8.6	105
870	Blood Biomarkers for the Diagnosis of Acute Cerebrovascular Diseases: A Prospective Cohort Study. Cerebrovascular Diseases, 2011, 32, 141-147.	1.7	40
871	A systematic review of event rates in clinical trials in diabetes mellitus: The importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design. American Heart Journal, 2011, 161, 210-219.e1.	2.7	51
872	Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet, The, 2011, 377, 1085-1095.	13.7	941
873	The case for diabetes screening: ADDITION-Europe. Lancet, The, 2011, 378, 106-108.	13.7	4
874	Accelerated Telomere Attrition Is Associated with Relative Household Income, Diet and Inflammation in the pSoBid Cohort. PLoS ONE, 2011, 6, e22521.	2.5	120
875	Associations of Gestational Weight Gain With Maternal Body Mass Index, Waist Circumference, and Blood Pressure Measured 16 Years After Pregnancy: The Avon Longitudinal Study of Parents and Children. Obstetrical and Gynecological Survey, 2011, 66, 599-600.	0.4	14
876	Combined cardiovascular and diabetes risk assessment in primary care. Diabetic Medicine, 2011, 28, 19-22.	2.3	12
877	The potential for a twoâ€stage diabetes risk algorithm combining nonâ€laboratoryâ€based scores with subsequent routine nonâ€fasting blood tests: results from prospective studies in older men and women. Diabetic Medicine, 2011, 28, 23-30.	2.3	34
878	Vascular function and cardiovascular risk factors in women with severe flushing. Clinical Endocrinology, 2011, 74, 97-103.	2.4	31
879	Adiponectin and raised mortality in type 1 diabetes: any credible explanatory mechanisms?*. Journal of Internal Medicine, 2011, 270, 339-342.	6.0	6
880	Lower thresholds for diagnosis and management of obesity in British South Asians. International Journal of Clinical Practice, 2011, 65, 378-379.	1.7	7
881	Childhood Obesity: A Ticking Time Bomb for Cardiovascular Disease?. Clinical Pharmacology and Therapeutics, 2011, 90, 174-178.	4.7	16
882	The Effect of TNF-alpha Blocking Therapy on Lipid Levels in Rheumatoid Arthritis: A Meta-Analysis. Seminars in Arthritis and Rheumatism, 2011, 41, 393-400.	3.4	84

#	Article	IF	CITATIONS
883	Stressed hearts in children with obesity and diabetes: a cause for concern?. Diabetologia, 2011, 54, 715-718.	6.3	5
884	AMP-activated protein kinase is activated in adipose tissue of individuals with type 2 diabetes treated with metformin: a randomised glycaemia-controlled crossover study. Diabetologia, 2011, 54, 1799-1809.	6.3	64
885	Inpatient costs for people with type 1 and type 2 diabetes in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia, 2011, 54, 2000-2008.	6. 3	25
886	Do men develop type 2 diabetes at lower body mass indices than women?. Diabetologia, 2011, 54, 3003-3006.	6.3	234
887	Replication of LDL GWAs hits in PROSPER/PHASE as validation for future (pharmaco)genetic analyses. BMC Medical Genetics, 2011, 12, 131.	2.1	35
888	Early life socioeconomic adversity is associated in adult life with chronic inflammation, carotid atherosclerosis, poorer lung function and decreased cognitive performance: a cross-sectional, population-based study. BMC Public Health, 2011, 11, 42.	2.9	92
889	Is vitamin D in rheumatoid arthritis a magic bullet or a mirage? The need to improve the evidence base prior to calls for supplementation. Arthritis and Rheumatism, 2011, 63, 1763-1769.	6.7	33
890	Hepatic VLDL Overproduction: Is Hyperinsulinemia or Insulin Resistance the Culprit?. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2032-2034.	3.6	13
891	Associations of gestational weight gain with maternal body mass index, waist circumference, and blood pressure measured 16 y after pregnancy: the Avon Longitudinal Study of Parents and Children (ALSPAC). American Journal of Clinical Nutrition, 2011, 93, 1285-1292.	4.7	188
892	Impact of Diabetes on Cardiovascular Disease Risk and All-Cause Mortality in Older Men. Archives of Internal Medicine, 2011, 171, 404-10.	3.8	227
893	Achieved Levels of HbA1c and Likelihood of Hospital Admission in People With Type 1 Diabetes in the Scottish Population. Diabetes Care, 2011, 34, 1992-1997.	8.6	32
894	Statins and the risk of new-onset diabetes. Current Opinion in Lipidology, 2011, 22, 460-466.	2.7	93
895	Are Lipid Ratios Less Susceptible to Change With Systemic Inflammation Than Individual Lipid Components in Patients With Rheumatoid Arthritis?. Angiology, 2011, 62, 167-175.	1.8	60
896	Sitting Time and Waist Circumference Are Associated With Glycemia in U.K. South Asians. Diabetes Care, 2011, 34, 1214-1218.	8.6	32
897	Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy. JAMA - Journal of the American Medical Association, 2011, 305, 2556.	7.4	1,197
898	The inverse relationship between alanine aminotransferase in the normal range and adverse cardiovascular and non-cardiovascular outcomes. International Journal of Epidemiology, 2011, 40, 1530-1538.	1.9	56
899	Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review Health Technology Assessment, 2011, 15, 1-110.	2.8	60
900	Vitamin D deficiency is common in patients with RA and linked to disease activity, but circulating levels are unaffected by TNF \hat{l}_{\pm} blockade: results from a prospective cohort study. Annals of the Rheumatic Diseases, 2011, 70, 1165-1167.	0.9	30

#	Article	IF	CITATIONS
901	Obesity is associated with fatal coronary heart disease independently of traditional risk factors and deprivation. Heart, 2011, 97, 564-568.	2.9	115
902	Ethnic Differences in Aortic Pulse Wave Velocity Occur in the Descending Aorta and May Be Related to Vitamin D. Hypertension, 2011, 58, 247-253.	2.7	44
903	Integrating Information From Novel Risk Factors With Calculated Risks. Circulation, 2011, 124, 741-745.	1.6	39
904	Circulating Interleukin-10 and Risk of Cardiovascular Events. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 2338-2344.	2.4	81
905	Association of Genetic Loci With Glucose Levels in Childhood and Adolescence. Diabetes, 2011, 60, 1805-1812.	0.6	103
906	Retinal Arteriolar Tortuosity and Cardiovascular Risk Factors in a Multi-Ethnic Population Study of 10-Year-Old Children; the Child Heart and Health Study in England (CHASE). Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 1933-1938.	2.4	82
907	Cerebral Microbleeds Are Predictive of Mortality in the Elderly. Stroke, 2011, 42, 638-644.	2.0	110
908	The incidence and risk factors for new onset atrial fibrillation in the PROSPER study. Europace, 2011, 13, 634-639.	1.7	53
909	Genetic variation at CHRNA5-CHRNA3-CHRNB4 interacts with smoking status to influence body mass index. International Journal of Epidemiology, 2011, 40, 1617-1628.	1.9	100
910	Genetic Predictors of Fibrin D-Dimer Levels in Healthy Adults. Circulation, 2011, 123, 1864-1872.	1.6	60
911	Effect of Socioeconomic Status on Mortality Among People With Type 2 Diabetes: A study from the Scottish Diabetes Research Network Epidemiology Group. Diabetes Care, 2011, 34, 1127-1132.	8.6	66
912	Simultaneous activation of the liver X receptors (LXRÂ and LXRÂ) drives murine collagen-induced arthritis disease pathology. Annals of the Rheumatic Diseases, 2011, 70, 2225-2228.	0.9	20
913	Mendelian Randomization Study of B-Type Natriuretic Peptide and Type 2 Diabetes: Evidence of Causal Association from Population Studies. PLoS Medicine, 2011, 8, e1001112.	8.4	92
914	Inflammatory Cytokines and Cardiovascular Risk. , 2011, , 235-249.		2
915	C-Reactive Protein and Genetic Variants and Cognitive Decline in Old Age: The PROSPER Study. PLoS ONE, 2011, 6, e23890.	2.5	28
916	Defining Obesity Cut-Off Points for Migrant South Asians. PLoS ONE, 2011, 6, e26464.	2.5	95
917	Associations Between Dietary Fiber and Inflammation, Hepatic Function, and Risk of Type 2 Diabetes in Older Men: Potential Mechanisms for the Benefits of Fiber on Diabetes Risk. Diabetes Care, 2010, 33, e44-e44.	8.6	1
918	Author reply: Which risk engines are best to assess CVD risk in diabetes?. Nature Reviews Endocrinology, 2010, 6, 116-116.	9.6	0

#	Article	IF	Citations
919	Association of existing diabetes, gestational diabetes and glycosuria in pregnancy with macrosomia and offspring body mass index, waist and fat mass in later childhood: findings from a prospective pregnancy cohort. Diabetologia, 2010, 53, 89-97.	6.3	191
920	Assessing prediction of diabetes in older adults using different adiposity measures: a 7Âyear prospective study in 6,923 older men and women. Diabetologia, 2010, 53, 890-898.	6.3	65
921	HbA1c: a useful cardiovascular risk marker in those without diabetes?. Diabetologia, 2010, 53, 2468-2469.	6.3	1
922	Pravastatin and cognitive function in the elderly. Results of the PROSPER study. Journal of Neurology, 2010, 257, 85-90.	3.6	238
923	Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: A narrative review and clinical perspective of prospective data. Hepatology, 2010, 52, 1156-1161.	7.3	244
924	Adiponectin and its association with bone mass accrual in childhood. Journal of Bone and Mineral Research, 2010, 25, 2212-2220.	2.8	43
925	Association of inflammatory mediators with premature atherosclerosis in rheumatoid arthritis and healthy controls: Comment on the article by Rho et al. Arthritis Care and Research, 2010, 62, 1052-1053.	3.4	2
926	Torcetrapib. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2010, 27, 339-340.	0.2	0
927	The interplay between inflammation, lipids and cardiovascular risk in rheumatoid arthritis: why ratios may be better. International Journal of Clinical Practice, 2010, 64, 1440-1443.	1.7	49
928	Simvastatin prevents inflammationâ€induced aortic stiffening and endothelial dysfunction. British Journal of Clinical Pharmacology, 2010, 70, 799-806.	2.4	30
929	Are there socioeconomic inequalities in cardiovascular risk factors in childhood, and are they mediated by adiposity? Findings from a prospective cohort study. International Journal of Obesity, 2010, 34, 1149-1159.	3.4	53
930	The effect of increased ambulatory activity on markers of chronic lowâ€grade inflammation: evidence from the PREPARE programme randomized controlled trial. Diabetic Medicine, 2010, 27, 1256-1263.	2.3	19
931	Which Circulating Antioxidant Vitamins Are Confounded by Socioeconomic Deprivation? The MIDSPAN Family Study. PLoS ONE, 2010, 5, e11312.	2.5	14
932	Fat Oxidation, Fitness and Skeletal Muscle Expression of Oxidative/Lipid Metabolism Genes in South Asians: Implications for Insulin Resistance?. PLoS ONE, 2010, 5, e14197.	2.5	83
933	Association of Maternal Weight Gain in Pregnancy With Offspring Obesity and Metabolic and Vascular Traits in Childhood. Circulation, 2010, 121, 2557-2564.	1.6	431
934	Interleukin-33 Induces Protective Effects in Adipose Tissue Inflammation During Obesity in Mice. Circulation Research, 2010, 107, 650-658.	4.5	285
935	Separating the Mechanism-Based and Off-Target Actions of Cholesteryl Ester Transfer Protein Inhibitors With <i>CETP</i> Gene Polymorphisms. Circulation, 2010, 121, 52-62.	1.6	96
936	Programming of Adiposity in Offspring of Mothers With Type 1 Diabetes at Age 7 Years. Diabetes Care, 2010, 33, 1080-1085.	8.6	65

#	Article	IF	CITATIONS
937	Lack of effect of TNFÂ blockade therapy on circulating adiponectin levels in patients with autoimmune disease: results from two independent prospective studies. Annals of the Rheumatic Diseases, 2010, 69, 1687-1690.	0.9	36
938	Genetic variation at the SLC23A1 locus is associated with circulating concentrations of l-ascorbic acid (vitamin C): evidence from 5 independent studies with >15,000 participants. American Journal of Clinical Nutrition, 2010, 92, 375-382.	4.7	102
939	Obesity in Children and Future Cardiometabolic Risk: Are blood tests necessary?. Diabetes Care, 2010, 33, 2711-2712.	8.6	4
940	First-Trimester Prediction of Gestational Diabetes Mellitus: Examining the Potential of Combining Maternal Characteristics and Laboratory Measures. Diabetes, 2010, 59, 3017-3022.	0.6	148
941	A Prospective Analysis of Elevated Fasting Glucose Levels and Cognitive Function in Older People. Diabetes, 2010, 59, 1601-1607.	0.6	75
942	Event Rates in Trials of Patients With Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2010, 303, 732.	7.4	1
943	Preeclampsia and Gestational Hypertension Are Associated With Childhood Blood Pressure Independently of Family Adiposity Measures. Circulation, 2010, 122, 1192-1199.	1.6	185
944	Lung Function and Risk of Type 2 Diabetes and Fatal and Nonfatal Major Coronary Heart Disease Events: Possible Associations With Inflammation. Diabetes Care, 2010, 33, 1990-1996.	8.6	79
945	Early Emergence of Ethnic Differences in Type 2 Diabetes Precursors in the UK: The Child Heart and Health Study in England (CHASE Study). PLoS Medicine, 2010, 7, e1000263.	8.4	127
946	Genome-Wide Association Study of Blood Pressure Extremes Identifies Variant near UMOD Associated with Hypertension. PLoS Genetics, 2010, 6, e1001177.	3 . 5	312
947	Tumour necrosis factor \hat{A} blockade reduces circulating N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis: results from a prospective cohort study. Annals of the Rheumatic Diseases, 2010, 69, 1281-1285.	0.9	53
948	Lipotoxicity in obese pregnancy and its potential role in adverse pregnancy outcome and obesity in the offspring. Clinical Science, 2010, 119, 123-129.	4.3	207
949	Fasting plasma glucose in non-diabetic participants and the risk for incident cardiovascular events, diabetes, and mortality: results from WOSCOPS 15-year follow-upâ€. European Heart Journal, 2010, 31, 1230-1236.	2.2	30
950	Unraveling the Directional Link between Adiposity and Inflammation: A Bidirectional Mendelian Randomization Approach. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 93-99.	3 . 6	120
951	Activation of Hemostasis and Decline in Cognitive Function in Older People. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 605-611.	2.4	37
952	Association between general and central adiposity in childhood, and change in these, with cardiovascular risk factors in adolescence: prospective cohort study. BMJ: British Medical Journal, 2010, 341, c6224-c6224.	2.3	238
953	Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk?. Annals of the Rheumatic Diseases, 2010, 69, 683-688.	0.9	135
954	Adiposity and cardiovascular risk factors in a large contemporary population of pre-pubertal children. European Heart Journal, 2010, 31, 3063-3072.	2.2	148

#	Article	IF	CITATIONS
955	Microemulsions for oral delivery of insulin: Design, development and evaluation in streptozotocin induced diabetic rats. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 76, 159-169.	4.3	118
956	Levels of physical activity and relationship with markers of diabetes and cardiovascular disease risk in 5474 white European and South Asian adults screened for type 2 diabetes. Preventive Medicine, 2010, 51, 290-294.	3.4	61
957	Physical activity, obesity and cardiometabolic risk factors in 9- to 10-year-old UK children of white European, South Asian and black African-Caribbean origin: the Child Heart And health Study in England (CHASE). Diabetologia, 2010, 53, 1620-1630.	6.3	111
958	NT-proBNP is associated with coronary heart disease risk in healthy older women but fails to enhance prediction beyond established risk factors: Results from the British Women's Heart and Health Study. Atherosclerosis, 2010, 209, 295-299.	0.8	10
959	Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet, The, 2010, 375, 735-742.	13.7	2,064
960	Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet, The, 2010, 375, 2215-2222.	13.7	3,807
961	Statins and risk of incident diabetes – Authors' reply. Lancet, The, 2010, 375, 2141-2142.	13.7	16
962	Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid Conditions. Journal of Investigative Dermatology, 2010, 130, 1785-1796.	0.7	554
963	EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Annals of the Rheumatic Diseases, 2010, 69, 325-331.	0.9	1,157
964	Changes in Ponderal Index and Body Mass Index across Childhood and Their Associations with Fat Mass and Cardiovascular Risk Factors at Age 15. PLoS ONE, 2010, 5, e15186.	2.5	80
965	Tackling obesity in adult primary care. Practitioner, 2010, 254, 31-2, 34, 3.	0.3	3
966	Reduced Glomerular Filtration Rate and Its Association with Clinical Outcome in Older Patients at Risk of Vascular Events: Secondary Analysis. PLoS Medicine, 2009, 6, e1000016.	8.4	54
967	B-Type Natriuretic Peptides and Cardiovascular Risk. Circulation, 2009, 120, 2177-2187.	1.6	340
968	Alanine Aminotransferase, Î ³ -Glutamyltransferase, and Incident Diabetes. Diabetes Care, 2009, 32, 741-750.	8.6	345
969	Adipocytokines and risk of stroke in older people: a nested case–control study. International Journal of Epidemiology, 2009, 38, 253-261.	1.9	57
970	Differences in atherosclerosis according to area level socioeconomic deprivation: cross sectional, population based study. BMJ: British Medical Journal, 2009, 339, b4170-b4170.	2.3	56
971	Which risk engines should be used to assess patients with diabetes?. Nature Reviews Endocrinology, 2009, 5, 302-303.	9.6	3
972	Hyperlipidaemia, statin use and the risk of developing rheumatoid arthritis. Annals of the Rheumatic Diseases, 2009, 68, 546-551.	0.9	63

#	Article	IF	CITATIONS
973	A Genome-Wide Association Study Reveals Variants in ARL15 that Influence Adiponectin Levels. PLoS Genetics, 2009, 5, e1000768.	3.5	148
974	C-Reactive Protein and Prognosis in Diabetes: Getting to the Heart of the Matter. Diabetes, 2009, 58, 798-799.	0.6	11
975	Leptin Predicts Diabetes but Not Cardiovascular Disease. Diabetes Care, 2009, 32, 308-310.	8.6	72
976	Apolipoprotein E Genotype, Plasma Cholesterol, and Cancer: A Mendelian Randomization Study. American Journal of Epidemiology, 2009, 170, 1415-1421.	3.4	53
977	Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Annals of the Rheumatic Diseases, 2009, 68, 460-469.	0.9	267
978	High Innate Production Capacity of Proinflammatory Cytokines Increases Risk for Death from Cancer: Results of the PROSPER Study. Clinical Cancer Research, 2009, 15, 7744-7748.	7.0	24
979	Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Diabetes Care, 2009, 32, 915-920.	8.6	61
980	Major Lipids, Apolipoproteins, and Risk of Vascular Disease. JAMA - Journal of the American Medical Association, 2009, 302, 1993.	7.4	2,205
981	Liver X receptor agonism promotes articular inflammation in murine collagenâ€induced arthritis. Arthritis and Rheumatism, 2009, 60, 2655-2665.	6.7	40
982	Are elevated circulating intercellular adhesion molecule 1 levels more strongly predictive of diabetes than vascular risk? Outcome of a prospective study in the elderly. Diabetologia, 2009, 52, 235-239.	6.3	17
983	Ceramides: A new player in the inflammation–insulin resistance paradigm?. Diabetologia, 2009, 52, 2475-2477.	6.3	33
984	Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. Clinical Endocrinology, 2009, 70, 815-828.	2.4	69
985	Authors' reply to: Statin therapy as the fundamental therapy for cardiovascular prevention: be careful. Clinical Endocrinology, 2009, 71, 456-457.	2.4	1
986	Metabolic syndrome: collapsing under its own weight?. Diabetic Medicine, 2009, 26, 457-459.	2.3	7
987	Erythrocytosis in offspring of mothers with Type 1 diabetes—are factors other than insulin critical determinants?. Diabetic Medicine, 2009, 26, 887-892.	2.3	15
988	Review: PCOS, insulin resistance and long-term risks for diabetes and vascular disease. British Journal of Diabetes and Vascular Disease, 2009, 9, 15-18.	0.6	9
989	Associations Between Dietary Fiber and Inflammation, Hepatic Function, and Risk of Type 2 Diabetes in Older Men. Diabetes Care, 2009, 32, 1823-1825.	8.6	115
990	Objectively Measured Physical Activity and Its Association With Adiponectin and Other Novel Metabolic Markers. Diabetes Care, 2009, 32, 468-473.	8.6	54

#	Article	IF	CITATIONS
991	Leptin and Coronary Heart Disease. Journal of the American College of Cardiology, 2009, 53, 167-175.	2.8	147
992	Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nature Reviews Cardiology, 2009, 6, 410-417.	13.7	252
993	Vascular dysfunction and alteration of novel and classic cardiovascular risk factors in mothers of growth restricted offspring. Atherosclerosis, 2009, 205, 244-250.	0.8	25
994	Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet, The, 2009, 373, 1765-1772.	13.7	1,234
995	Intensive glucose control and cardiovascular outcomes – Authors' reply. Lancet, The, 2009, 374, 524.	13.7	O
996	Triglycerides and coronary heart disease: have recent insights yielded conclusive answers?. Current Opinion in Lipidology, 2009, 20, 275-281.	2.7	15
997	Lipoprotein metabolism and vascular complications in pregnancy. Clinical Lipidology, 2009, 4, 91-102.	0.4	19
998	More knocks to the oxidation hypothesis for vascular disease?. Clinical Science, 2009, 116, 41-43.	4.3	3
999	Are Markers of Inflammation More Strongly Associated with Risk for Fatal Than for Nonfatal Vascular Events?. PLoS Medicine, 2009, 6, e1000099.	8.4	87
1000	The Effect of Pregnancy on Energy Metabolism, Body Composition, and Endothelial Function. , 2009, , 207-222.		0
1001	Novel biochemical risk factors for type 2 diabetes: pathogenic insights or prediction possibilities?. Diabetologia, 2008, 51, 926-940.	6.3	131
1002	Inflammation, insulin resistance, and cardiovascular disease: Cause or correlate?. Current Cardiovascular Risk Reports, 2008, 2, 53-59.	2.0	0
1003	Food, fatness and facts: the need for a standard message. International Journal of Clinical Practice, 2008, 62, 677-678.	1.7	0
1004	The effects of 8â€f months of metformin on circulating GGT and ALT levels in obese women with polycystic ovarian syndrome. International Journal of Clinical Practice, 2008, 62, 1337-1343.	1.7	34
1005	Why metabolic syndrome criteria have not made prime time: a view from the clinic. International Journal of Obesity, 2008, 32, S30-S34.	3.4	27
1006	Does Low to Moderate Alcohol Intake Protect Against Cognitive Decline in Older People?. Journal of the American Geriatrics Society, 2008, 56, 2217-2224.	2.6	42
1007	Depotâ€specific steroidogenic gene transcription in human adipose tissue. Clinical Endocrinology, 2008, 69, 848-854.	2.4	74
1008	Adiponectin in childhood. Pediatric Obesity, 2008, 3, 130-140.	3.2	60

#	Article	IF	CITATIONS
1009	Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clinical Science, 2008, 115, 141-150.	4.3	247
1010	Walking and inflammatory markers in individuals screened for type 2 diabetes. Preventive Medicine, 2008, 47, 417-421.	3.4	16
1011	The association of insulin-like-growth factor 1 (IGF-1) with incident coronary heart disease in women: Findings from the prospective British Women's Heart and Health Study. Atherosclerosis, 2008, 201, 198-204.	0.8	22
1012	Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet, The, 2008, 371, 1927-1935.	13.7	416
1013	Ankle brachial index vs metabolic syndrome for risk prediction – Authors' reply. Lancet, The, 2008, 372, 1221-1222.	13.7	3
1014	SERRS immunoassay for quantitative human CRP analysis. Analyst, The, 2008, 133, 1355.	3. 5	40
1015	IL-33 reduces the development of atherosclerosis. Journal of Experimental Medicine, 2008, 205, 339-346.	8.5	574
1016	Distribution of Adiponectin, Leptin, and Metabolic Correlates of Insulin Resistance: A Longitudinal Study in British Children; 1: Prepuberty (EarlyBird 15). Clinical Chemistry, 2008, 54, 1298-1306.	3.2	23
1017	Metabolic Syndrome and Incident Diabetes. Diabetes Care, 2008, 31, 1898-1904.	8.6	491
1018	Tissue Plasminogen Activator, von Willebrand Factor, and Risk of Type 2 Diabetes in Older Men. Diabetes Care, 2008, 31, 995-1000.	8.6	39
1019	Risk of metabolic and vascular disease in South Asians: potential mechanisms for increased insulin resistance. Future Lipidology, 2008, 3, 411-424.	0.5	19
1020	Effects of atorvastatin added to inhaled corticosteroids on lung function and sputum cell counts in atopic asthma. Thorax, 2008, 63, 1070-1075.	5.6	89
1021	Role of Adiponectin in Matching of Fetal and Placental Weight in Mothers With Type 1 Diabetes. Diabetes Care, 2008, 31, 1123-1125.	8.6	13
1022	Adiponectin, Diabetes, and Coronary Heart Disease in Older Persons: Unraveling the Paradox. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3299-3301.	3.6	54
1023	Polycystic Ovarian Syndrome, Biomarkers, and Metformin: Research, Risk, and Reality. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 34-36.	3. 6	4
1024	Allopurinol Use Yields Potentially Beneficial Effects on Inflammatory Indices in Those With Recent Ischemic Stroke. Stroke, 2008, 39, 3303-3307.	2.0	75
1025	High Molecular Weight Adiponectin Is Not Associated with Incident Coronary Heart Disease in Older Women: A Nested Prospective Case-Control Study. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1846-1849.	3.6	54
1026	Novel antecedent plasma biomarkers of cardiovascular disease: improved evaluation methods and comparator benchmarks raise the bar. Current Opinion in Lipidology, 2008, 19, 563-571.	2.7	13

#	Article	IF	CITATIONS
1027	Inflammation and Endothelial Activation Is Evident at Birth in Offspring of Mothers With Type 1 Diabetes. Diabetes, 2007, 56, 2697-2704.	0.6	56
1028	Adipokines and Risk of Type 2 Diabetes in Older Men. Diabetes Care, 2007, 30, 1200-1205.	8.6	167
1029	Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker. European Journal of Heart Failure, 2007, 9, 429-434.	7.1	50
1030	Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. European Heart Journal, 2007, 28, 829-835.	2.2	150
1031	Circulating concentrations of insulin markers and coronary heart disease: a quantitative review of 19 Western prospective studies. European Heart Journal, 2007, 28, 2491-2497.	2.2	57
1032	Circulating Adiponectin Levels and Mortality in Elderly Men With and Without Cardiovascular Disease and Heart Failure. Archives of Internal Medicine, 2007, 167, 1510.	3.8	156
1033	Serial Metabolic Measurements and Conversion to Type 2 Diabetes in the West of Scotland Coronary Prevention Study. Diabetes, 2007, 56, 984-991.	0.6	109
1034	C-Reactive Protein and Prediction of Coronary Heart Disease and Global Vascular Events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation, 2007, 115, 981-989.	1.6	112
1035	Gamma-Glutamyltransferase Is Associated With Incident Vascular Events Independently of Alcohol Intake. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 2729-2735.	2.4	253
1036	Behavior of Insulin Resistance and Its Metabolic Correlates in Prepubertal Children. Diabetes Care, 2007, 30, 2962-2964.	8.6	15
1037	Glomerular hyperfiltration: A new marker of metabolic risk. Kidney International, 2007, 71, 816-821.	5.2	200
1038	Inflammation and ischaemic stroke. Current Opinion in Neurology, 2007, 20, 334-342.	3.6	229
1039	Reproducibility and Repeatability of Peripheral Microvascular Assessment Using Iontophoresis in Conjunction With Laser Doppler Imaging. Journal of Cardiovascular Pharmacology, 2007, 50, 343-349.	1.9	13
1040	Plasma leptin: Associations with metabolic, inflammatory and haemostatic risk factors for cardiovascular disease. Atherosclerosis, 2007, 191, 418-426.	0.8	180
1041	Inflammatory suppression rapidly attenuates microvascular dysfunction in rheumatoid arthritis. Atherosclerosis, 2007, 192, 391-395.	0.8	50
1042	Benefits of salmon eating on traditional and novel vascular risk factors in young, non-obese healthy subjects. Atherosclerosis, 2007, 193, 213-221.	0.8	75
1043	Effect of prior moderate exercise on postprandial metabolism in men with type 2 diabetes: Heterogeneity of responses. Atherosclerosis, 2007, 194, 134-143.	0.8	35
1044	IGF-1 and Leptin Associate With Fetal HDL Cholesterol at Birth: Examination in Offspring of Mothers With Type 1 Diabetes. Diabetes, 2007, 56, 2705-2709.	0.6	29

#	Article	IF	CITATIONS
1045	Low-Dose Docosahexaenoic Acid Lowers Diastolic Blood Pressure in Middle-Aged Men and Women. Journal of Nutrition, 2007, 137, 973-978.	2.9	80
1046	Corrigendum to "Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker―[European Journal of Heart Failure 9/4 (2007) 429-434]. European Journal of Heart Failure, 2007, 9, 1074-1074.	7.1	0
1047	Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: A double-blind, placebo-controlled study. Arthritis and Rheumatism, 2007, 56, 831-839.	6.7	110
1048	Nonâ€alcoholic fatty liver disease: what is it, when does it occur, and why does it matter?. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2007, 24, 310-316.	0.2	1
1049	Associations of adiponectin with metabolic and vascular risk parameters in the British Regional Heart Study reveal stronger links to insulin resistance-related than to coronory heart disease risk-related parameters. International Journal of Obesity, 2007, 31, 1089-1098.	3.4	43
1050	Effects of low-dose continuous combined hormone replacement therapy on glucose homeostasis and markers of cardiovascular risk in women with typeÂ2 diabetes. Clinical Endocrinology, 2007, 66, 27-34.	2.4	30
1051	Vascular cell adhesion molecule-1: a viable therapeutic target for atherosclerosis?. International Journal of Clinical Practice, 2007, 61, 697-701.	1.7	70
1052	The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. European Journal of Epidemiology, 2007, 22, 839-869.	5.7	153
1053	The changing role of the clinical laboratory in the investigation of polycystic ovarian syndrome. Clinical Biochemist Reviews, 2007, 28, 79-92.	3.3	12
1054	Does rimonabant pull its weight for type 2 diabetes?. Lancet, The, 2006, 368, 1632-1634.	13.7	14
1055	Effects of a moderate exercise session on postprandial lipoproteins, apolipoproteins and lipoprotein remnants in middle-aged men. Atherosclerosis, 2006, 185, 87-96.	0.8	47
1056	CVD risk factors and ethnicityâ€"A homogeneous relationship?. Atherosclerosis Supplements, 2006, 7, 11-19.	1.2	169
1057	Effects of Metformin on Microvascular Function and Exercise Tolerance in Women With Angina and Normal Coronary Arteries. Journal of the American College of Cardiology, 2006, 48, 956-963.	2.8	132
1058	Obesity and reproduction. BMJ: British Medical Journal, 2006, 333, 1159-1162.	2.3	108
1059	The metabolic syndrome: should current criteria influence clinical practice?. Current Opinion in Lipidology, 2006, 17, 404-411.	2.7	29
1060	A comparison of glycaemic and metabolic control over time among South Asian and European patients with Type 2 diabetes: results from follow-up in a routine diabetes clinic. Diabetic Medicine, 2006, 23, 94-98.	2.3	89
1061	Effects of HRT on liver enzyme levels in women with type 2 diabetes: a randomized placebo-controlled trial. Clinical Endocrinology, 2006, 65, 40-44.	2.4	114
1062	Do known risk factors explain the higher coronary heart disease mortality in South Asian compared with European men? Prospective follow-up of the Southall and Brent studies, UK. Diabetologia, 2006, 49, 2580-2588.	6.3	219

#	Article	IF	CITATIONS
1063	Microvascular Function, Metabolic Syndrome, and Novel Risk Factor Status in Women With Cardiac Syndrome X. American Journal of Cardiology, 2006, 97, 1727-1731.	1.6	39
1064	Vitamin antioxidants, lipid peroxidation and the systemic inflammatory response in patients with prostate cancer. International Journal of Cancer, 2006, 118, 1051-1053.	5.1	36
1065	Obesity—can we turn the tide?. BMJ: British Medical Journal, 2006, 333, 1261-1264.	2.3	26
1066	High sensitivity C-reactive protein in cardiovascular disease and type 2 diabetes: evidence for a clinical role?. British Journal of Diabetes and Vascular Disease, 2006, 6, 5-8.	0.6	1
1067	Adiponectin and Coronary Heart Disease. Circulation, 2006, 114, 623-629.	1.6	395
1068	High sensitivity C-reactive protein and cardiovascular disease: an association built on unstable foundations?. Annals of Clinical Biochemistry, 2006, 43, 252-256.	1.6	13
1069	Insight into the nature of the CRP–coronary event association using Mendelian randomization. International Journal of Epidemiology, 2006, 35, 922-931.	1.9	159
1070	"Anti-Inflammatory" Drugs and Their Effects on Type 2 Diabetes. Diabetes Technology and Therapeutics, 2006, 8, 18-27.	4.4	41
1071	Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions. Current Opinion in Rheumatology, 2005, 17, 286-292.	4.3	94
1072	Changes in booking body mass index over a decade: retrospective analysis from a Glasgow Maternity Hospital. BJOG: an International Journal of Obstetrics and Gynaecology, 2005, 112, 1431-1433.	2.3	216
1073	Impact of ethnicity on metabolic disturbance, vascular dysfunction and atherothrombotic cardiovascular disease. Diabetes, Obesity and Metabolism, 2005, 7, 463-470.	4.4	15
1074	Growth hormone replacement reduces C-reactive protein and large-artery stiffness but does not alter endothelial function in patients with adult growth hormone deficiency. Clinical Endocrinology, 2005, 62, 473-479.	2.4	36
1075	Effect of CLA supplementation on immune function in young healthy volunteers. European Journal of Clinical Nutrition, 2005, 59, 508-517.	2.9	140
1076	The Associations of Physical Activity and Adiposity with Alanine Aminotransferase and Gamma-Glutamyltransferase. American Journal of Epidemiology, 2005, 161, 1081-1088.	3.4	157
1077	Review: Diabetes and cardiac disease in South Asians. British Journal of Diabetes and Vascular Disease, 2005, 5, 253-259.	0.6	10
1078	Adiponectin Predicts Insulin Resistance But Not Endothelial Function in Young, Healthy Adolescents. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4615-4621.	3.6	37
1079	Plasma Adiponectin Levels Are Associated with Insulin Resistance, But Do Not Predict Future Risk of Coronary Heart Disease in Women. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5677-5683.	3.6	200
1080	Metformin and Weight Loss in Obese Women with Polycystic Ovary Syndrome: Comparison of Doses. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4593-4598.	3.6	135

#	Article	IF	CITATIONS
1081	Metabolic syndrome criteria: ready for clinical prime time or work in progress?The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology European Heart Journal, 2005, 26, 1249-1251.	2.2	12
1082	Metformin reduces serum mi $^1/2$ llerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. Fertility and Sterility, 2005, 83, 130-136.	1.0	81
1083	Insulin resistance and the metabolic syndrome as predictors of cardiovascular risk: where are we now?. Minerva Endocrinologica, 2005, 30, 121-38.	1.8	2
1084	Effects of low-dose continuous combined HRT on vascular function in women with type 2 diabetes. Diabetes and Vascular Disease Research, 2004, 1, 82-88.	2.0	15
1085	Score Based on Hypoalbuminemia and Elevated C-Reactive Protein Predicts Survival in Patients With Advanced Gastrointestinal Cancer. Nutrition and Cancer, 2004, 48, 171-173.	2.0	89
1086	Metabolic Syndrome and Diabetes Mellitus. Circulation, 2004, 109, E23.	1.6	3
1087	Comparison of the Associations of Apolipoprotein B and Non-High-Density Lipoprotein Cholesterol With Other Cardiovascular Risk Factors in Patients With the Metabolic Syndrome in the Insulin Resistance Atherosclerosis Study. Circulation, 2004, 110, 2687-2693.	1.6	135
1088	Do statins offer therapeutic potential in inflammatory arthritis?. Annals of the Rheumatic Diseases, 2004, 63, 1535-1537.	0.9	29
1089	Insulin resistance as a contributor to myocardial ischaemia independent of obstructive coronary atheroma: a role for insulin sensitisation?. Heart, 2004, 90, 1379-1383.	2.9	14
1090	Inverse Association Between Birth Weight and C-Reactive Protein Concentrations in the MIDSPAN Family Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 583-587.	2.4	94
1091	Women with polycystic ovary syndrome (PCOS) often undergo protracted treatment with metformin and are disinclined to stop: indications for a change in licensing arrangements?. Human Reproduction, 2004, 19, 2718-2720.	0.9	16
1092	Short- and Long-Term Changes in Plasma Inflammatory Markers Associated With Preeclampsia. Hypertension, 2004, 44, 708-714.	2.7	253
1093	Higher carotid-radial pulse wave velocity in healthy offspring of patients with Type 2 diabetes. Diabetic Medicine, 2004, 21, 262-266.	2.3	32
1094	The relationship between interleukin-6 and C-reactive protein in patients with benign and malignant prostate disease. British Journal of Cancer, 2004, 91, 1755-1757.	6.4	31
1095	Serum C-reactive protein and lipids in ultra-Marathon runners. American Journal of Cardiology, 2004, 94, 125-126.	1.6	22
1096	Elevated Alanine Aminotransferase Predicts New-Onset Type 2 Diabetes Independently of Classical Risk Factors, Metabolic Syndrome, and C-Reactive Protein in the West of Scotland Coronary Prevention Study. Diabetes, 2004, 53, 2855-2860.	0.6	324
1097	Effects of prior moderate exercise on postprandial metabolism and vascular function in lean and centrally obese men. Journal of the American College of Cardiology, 2004, 44, 2375-2382.	2.8	124
1098	Pre-eclampsia and cardiovascular disease: metabolic syndrome of pregnancy?. Atherosclerosis, 2004, 175, 189-202.	0.8	250

#	Article	IF	Citations
1099	Fetal cord plasma lipoprotein status in uncomplicated human pregnancies and in pregnancies complicated by pre-eclampsia and intrauterine growth restriction. Atherosclerosis, 2004, 176, 181-187.	0.8	70
1100	Do pregnancy complications and CVD share common antecedents?. Atherosclerosis Supplements, 2004, 5, 3-7.	1.2	63
1101	Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet, The, 2004, 363, 2015-2021.	13.7	750
1102	Statins and rheumatoid arthritis. Lancet, The, 2004, 364, 1855.	13.7	0
1103	Divergent metabolic and vascular phenotypes in pre-eclampsia and intrauterine growth restriction. Journal of Hypertension, 2004, 22, 2177-2183.	0.5	42
1104	Metabolic, Inflammatory, and Hemostatic Effects of a Low-Dose Continuous Combined HRT in Women With Type 2 Diabetes: Potentially Safer With Respect to Vascular Risk. Obstetrical and Gynecological Survey, 2004, 59, 524-525.	0.4	2
1105	Inflammation and endothelial dysfunction: intimate companions in the pathogenesis of vascular disease?. Clinical Science, 2004, 106, 443-445.	4.3	45
1106	Lower concentrations of carotenoids in the critically ill patient are related to a systemic inflammatory response and increased lipid peroxidation. Clinical Nutrition, 2003, 22, 459-462.	5.0	34
1107	Metabolic, inflammatory and haemostatic effects of a low-dose continuous combined HRT in women with type 2 diabetes: potentially safer with respect to vascular risk?. Clinical Endocrinology, 2003, 59, 682-689.	2.4	38
1108	Microvascular dysfunction: a link between pre-eclampsia and maternal coronary heart disease. BJOG: an International Journal of Obstetrics and Gynaecology, 2003, 110, 1029-1031.	2.3	114
1109	Explaining How "High-Grade―Systemic Inflammation Accelerates Vascular Risk in Rheumatoid Arthritis. Circulation, 2003, 108, 2957-2963.	1.6	812
1110	Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study. Circulation, 2003, 108, 414-419.	1.6	1,342
1111	Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet, The, 2003, 361, 1894-1901.	13.7	229
1112	Paradoxical Elevation in Adiponectin Concentrations in Women With Preeclampsia. Hypertension, 2003, 42, 891-894.	2.7	148
1113	Commentary: Documenting ethnic variations in vascular risk: where do we go from here?. British Journal of Diabetes and Vascular Disease, 2003, 3, 294-294.	0.6	0
1114	Enhancement of Endothelial Function by Pregnancy. Diabetes Care, 2003, 26, 475-479.	8.6	28
1115	Comparison of the Associations of Apolipoprotein B and Low-Density Lipoprotein Cholesterol With Other Cardiovascular Risk Factors in the Insulin Resistance Atherosclerosis Study (IRAS). Circulation, 2003, 108, 2312-2316.	1.6	122
1116	Metformin or Antiandrogen in the Treatment of Hirsutism in Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4116-4123.	3.6	186

#	Article	IF	CITATIONS
1117	A Novel Anti-Inflammatory Role for Simvastatin in Inflammatory Arthritis. Journal of Immunology, 2003, 170, 1524-1530.	0.8	399
1118	Strikingly Low Circulating CRP Concentrations in Ultramarathon Runners Independent of Markers of Adiposity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 1640-1644.	2.4	81
1119	Prospective Relation of C-Reactive Protein With Type 2 Diabetes: Response to Snijder et al Diabetes Care, 2003, 26, 1657-1658.	8.6	4
1120	Classic and Novel Risk Factor Parameters in Women With a History of Preeclampsia. Hypertension, 2003, 42, 39-42.	2.7	163
1121	Evidence for Tissue Selectivity of the Synthetic Androgen 7α-Methyl-19-Nortestosterone in Hypogonadal Men. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 2784-2793.	3.6	68
1122	Specific elevation in plasma tissue plasminogen activator antigen concentrations in South Asians relative to Europeans. Blood Coagulation and Fibrinolysis, 2003, 14, 755-760.	1.0	19
1123	The G-to-T point mutation in codon 34 of the factor XIII gene and the risk of pre-eclampsia. Blood Coagulation and Fibrinolysis, 2003, 14, 155-157.	1.0	6
1124	Maternal docosahexaenoic acid supplementation and fetal accretion. British Journal of Nutrition, 2003, 90, 135-145.	2.3	93
1125	Low Triglyceride, Not Low Cholesterol Concentration, Independently Predicts Poor Outcome following Acute Stroke. Cerebrovascular Diseases, 2003, 16, 76-82.	1.7	72
1126	Statins in the Era of Evidence-Based Medicine — Who Will Not "Prosper�. Scottish Medical Journal, 2003, 48, 64-68.	1.3	2
1127	Maternal docosahexaenoic acid supplementation and fetal accretion. British Journal of Nutrition, 2003, 90, 135-145.	2.3	25
1128	Intercellular adhesion molecule-1 (ICAM-1) expression is upregulated by thrombin in human monocytes and THP-1 cells in vitro and in pregnant subjects in vivo. Thrombosis and Haemostasis, 2003, 89, 1043-51.	3.4	2
1129	Microvascular dysfunction: a link between pre-eclampsia and maternal coronary heart disease. BJOG: an International Journal of Obstetrics and Gynaecology, 2003, 110, 1029-31.	2.3	31
1130	Maternal Obesity Is Associated with Dysregulation of Metabolic, Vascular, and Inflammatory Pathways. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4231-4237.	3.6	556
1131	Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening?. BMJ: British Medical Journal, 2002, 325, 157-160.	2.3	681
1132	Prospective Study of C-Reactive Protein in Relation to the Development of Diabetes and Metabolic Syndrome in the Mexico City Diabetes Study. Diabetes Care, 2002, 25, 2016-2021.	8.6	453
1133	Elimination of Electrically Induced Iontophoretic Artefacts: Implications for Non-Invasive Assessment of Peripheral Microvascular Function. Journal of Vascular Research, 2002, 39, 447-455.	1.4	65
1134	Supraphysiological concentrations of estradiol in menopausal women given repeated implant therapy do not adversely affect lipid profiles. Human Reproduction, 2002, 17, 825-829.	0.9	9

#	Article	IF	Citations
1135	Hormone replacement therapy can augment vascular relaxation in post-menopausal women with type 2 diabetes. Human Reproduction, 2002, 17, 497-502.	0.9	22
1136	A Specific Elevation in Tissue Plasminogen Activator Antigen in Women with Polycystic Ovarian Syndrome. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3287-3290.	3.6	62
1137	Circulating Concentrations of "Free" Leptin in Relation to Fat Mass and Appetite in Gastrointestinal Cancer Patients. Nutrition and Cancer, 2002, 44, 157-160.	2.0	29
1138	Ovarian Function and Metabolic Factors in Women with Oligomenorrhea Treated with Metformin in a Randomized Double Blind Placebo-Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 569-574.	3.6	309
1139	Factors Critical to Iontophoretic Assessment of Vascular Reactivity: Implications for Clinical Studies of Endothelial Dysfunction. Journal of Cardiovascular Pharmacology, 2002, 39, 9-17.	1.9	69
1140	C-Reactive Protein Is an Independent Predictor of Risk for the Development of Diabetes in the West of Scotland Coronary Prevention Study. Diabetes, 2002, 51, 1596-1600.	0.6	667
1141	The relationship between reduced vitamin antioxidant concentrations and the systemic inflammatory response in patients with common solid tumours. Clinical Nutrition, 2002, 21, 161-164.	5.0	51
1142	Relationship of carotenoid and vitamins A and E with the acute inflammatory response in acute pancreatitis. British Journal of Surgery, 2002, 87, 301-305.	0.3	62
1143	The relationship of circulating insulinâ€like growth factor 1, its binding proteinâ€3, prostateâ€specific antigen and Câ€reactive protein with disease stage in prostate cancer. BJU International, 2002, 89, 396-399.	2.5	36
1144	Analysis of Obesity and Hyperinsulinemia in the Development of Metabolic Syndrome: San Antonio Heart Study. Obesity, 2002, 10, 923-931.	4.0	155
1145	Pre-hCG intrafollicular vascularity and serial pre- and post-hCG plasma VEGF in women at risk of the ovarian hyperstimulation syndrome Fertility and Sterility, 2001, 76, S89-S90.	1.0	0
1146	Attenuation of endothelin-1 induced vasoconstriction by $17\hat{l}^2$ estradiol is not sustained during long-term therapy in postmenopausal women with coronary heart disease. Journal of the American College of Cardiology, 2001, 37, 1367-1373.	2.8	23
1147	Plasma ascorbic acid and risk of heart disease and cancer. Lancet, The, 2001, 357, 2134.	13.7	0
1148	La atenuaci \tilde{A}^3 n de la vasoconstricci \tilde{A}^3 n inducida por la endotelina 1 mediante 17 betaestradiol no se mantiene durante el tratamiento a largo plazo en mujeres posmenop \tilde{A}_1 usicas con coronariopat \tilde{A} a. Cl \tilde{A} nica E Investigaci \tilde{A}^3 n En Arteriosclerosis, 2001, 13, 283-284.	0.8	0
1149	Low Grade Chronic Inflammation in Women with Polycystic Ovarian Syndrome. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2453-2455.	3 . 6	546
1150	Pravastatin and the Development of Diabetes Mellitus. Circulation, 2001, 103, 357-362.	1.6	824
1151	Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clinical Endocrinology, 2001, 54, 447-453.	2.4	139
1152	Fatty acid status of women of reproductive age. European Journal of Clinical Nutrition, 2001, 55, 518-524.	2.9	11

#	Article	IF	Citations
1153	Relation of C-reactive protein to body fat distribution and features of the metabolic syndrome in Europeans and South Asians. International Journal of Obesity, 2001, 25, 1327-1331.	3.4	315
1154	Antenatal Waist Circumference and Hypertension Risk. Obstetrics and Gynecology, 2001, 97, 268-271.	2.4	32
1155	Plasma Leptin and the Risk of Cardiovascular Disease in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation, 2001, 104, 3052-3056.	1.6	748
1156	Circulating leptin concentrations and ovarian function in polycystic ovary syndrome. European Journal of Endocrinology, 2001, 145, 289-294.	3.7	30
1157	Review: Adipose tissue: passive sump or active pump?. British Journal of Diabetes and Vascular Disease, 2001, 1, 110-114.	0.6	7
1158	The Effects of Transdermal Estradiol in Combination with Oral Norethisterone on Lipoproteins, Coagulation, and Endothelial Markers in Postmenopausal Women with Type 2 Diabetes: A Randomized, Placebo-Controlled Study. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1140-1143.	3.6	66
1159	Measurement of the Systemic Inflammatory Response Predicts Cancer-Specific and Non-Cancer Survival in Patients With Cancer. Nutrition and Cancer, 2001, 41, 64-69.	2.0	53
1160	The Glasgow Outcome, APCR and Lipid (GOAL) Pregnancy Study: significance of pregnancy associated activated protein C resistance. Thrombosis and Haemostasis, 2001, 85, 30-5.	3 . 4	8
1161	Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clinical Science, 2000, 98, 531-535.	4.3	191
1162	Effect of the inflammatory response on trace element and vitamin status. Annals of Clinical Biochemistry, 2000, 37, 289-297.	1.6	176
1163	Changes in micronutrient concentrations following anti-inflammatory treatment in patients with gastrointestinal cancer. Nutrition, 2000, 16, 425-428.	2.4	51
1164	Further Characterization of a Novel Triacylglycerol Hydrolase Activity (pH6.0 optimum) from Microvillous Membranes from Human Term Placenta. Placenta, 2000, 21, 813-823.	1.5	25
1165	THE CO-ORDINATED CYTOKINE/HORMONE RESPONSE TO ACUTE INJURY INCORPORATES LEPTIN. Cytokine, 2000, 12, 1042-1045.	3.2	49
1166	Insulin Resistance â€" The Metabolic Syndrome, Edited by G.M. Reaven, A. Laws. ISBN 0-896-03588-3 S/4674199. Atherosclerosis, 2000, 152, 533.	0.8	0
1167	Lipoprotein (a) levels in normal pregnancy and in pregnancy complicated with pre-eclampsia. Atherosclerosis, 2000, 148, 407-411.	0.8	41
1168	Relationship between myometrial resistance artery behavior and circulating lipid composition. American Journal of Obstetrics and Gynecology, 1999, 180, 381-386.	1.3	14
1169	Lipids and the pathogenesis of pre-eclampsia. Current Obstetrics & Gynaecology, 1999, 9, 190-195.	0.2	8
1170	Hormone replacement therapy and C-reactive protein. Lancet, The, 1999, 354, 1908.	13.7	2

#	Article	IF	Citations
1171	Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes. Lancet, The, 1999, 354, 487-488.	13.7	85
1172	Dietary flavonols protect diabetic human lymphocytes against oxidative damage to DNA. Diabetes, 1999, 48, 176-181.	0.6	162
1173	HELLP syndrome: mechanisms and management. British Journal of Hospital Medicine, 1999, 60, 243-249.	0.2	15
1174	Lipid and Lipoprotein Concentrations in Pregnancies Complicated by Intrauterine Growth Restriction. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 128-130.	3.6	64
1175	A longitudinal study of the relationships between haemostatic, lipid, and oestradiol changes during normal human pregnancy. Thrombosis and Haemostasis, 1999, 81, 71-5.	3.4	14
1176	Essential fatty acids in relation to pregnancy complications and fetal development. BJOG: an International Journal of Obstetrics and Gynaecology, 1998, 105, 1248-1255.	2.3	33
1177	Associations of indices of adiposity with atherogenic lipoprotein subfractions. International Journal of Obesity, 1998, 22, 432-439.	3.4	86
1178	Hormone replacement therapy in Type 2 diabetes mellitus: a cardiovascular perspective. , 1998, 15, 631-633.		7
1179	Insulin-sensitising agents in polycystic-ovary syndrome. Lancet, The, 1998, 351, 305-307.	13.7	48
1180	Plasma apolipoprotein A1 and birthweight. Lancet, The, 1998, 351, 835.	13.7	1
1181	Inhibitors of angiotensin-l-converting enzyme and risk of cancer. Lancet, The, 1998, 352, 1151.	13.7	8
1182	The atherogenic lipoprotein phenotype and vascular endothelial dysfunction. Atherosclerosis, 1998, 138, 229-235.	0.8	151
1183	Changes in the Concentrations of Plasma Selenium and Selenoproteins after Minor Elective Surgery: Further Evidence for a Negative Acute Phase Response?. Clinical Chemistry, 1998, 44, 1764-1766.	3.2	94
1184	Leptin levels in pregnancy: marker for fat accumulation and mobilization?. Acta Obstetricia Et Gynecologica Scandinavica, 1998, 77, 278-83.	2.8	28
1185	Changes in the concentrations of plasma selenium and selenoproteins after minor elective surgery: further evidence for a negative acute phase response?. Clinical Chemistry, 1998, 44, 1764-6.	3.2	30
1186	Effect of weight loss and the inflammatory response on leptin concentrations in gastrointestinal cancer patients. Clinical Cancer Research, 1998, 4, 2977-9.	7.0	58
1187	Lipoprotein Subfraction Changes in Normal Pregnancy: Threshold Effect of Plasma Triglyceride on Appearance of Small, Dense Low Density Lipoprotein 1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2483-2491.	3.6	154
1188	Acuteâ€phase reactants and plasma trace element concentrations in nonâ€small cell lung cancer patients and controls. Nutrition and Cancer, 1997, 28, 308-312.	2.0	58

#	Article	IF	CITATIONS
1189	Lipoprotein subfraction concentrations in preeclampsia: Pathogenic parallels to atherosclerosis. Obstetrics and Gynecology, 1997, 89, 403-408.	2.4	243
1190	Lipoprotein Subfraction Changes in Normal Pregnancy: Threshold Effect of Plasma Triglyceride on Appearance of Small, Dense Low Density Lipoprotein. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2483-2491.	3 . 6	116
1191	Abnormal antioxidant vitamin and carotenoid status in chronic renal failure. QJM - Monthly Journal of the Association of Physicians, 1996, 89, 765-770.	0.5	62
1192	Coronary disease in British South Asians. Practice Nursing, 1996, 7, 22-24.	0.1	0
1193	Hormone Replacement Therapy and Cardiovascular Risk in Post-menopausal Women with NIDDM. Diabetic Medicine, 1996, 13, 782-788.	2.3	10
1194	Potential pathogenic roles of aberrant lipoprotein and fatty acid metabolism in pre-eclampsia. BJOG: an International Journal of Obstetrics and Gynaecology, 1996, 103, 614-620.	2.3	120
1195	Fibrinolytic markers in pregnancy. Blood Coagulation and Fibrinolysis, 1995, 6, 157.	1.0	0
1196	Pathogenesis of Atherosclerosis and Vascular Disease in Type 2 Diabetes. , 0, , 16-36.		1
1197	Short Communication: Vitamin D and COVID-19 infection and mortality in UK Biobank., 0, , .		8